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Abstract: Nanomaterials, in addition to their small size, possess unique physicochemical properties that 
differ from the bulk materials, making them ideal for a host of novel applications. Magnetic nanoparticle 
(MNP) is one important class of nanomaterials that have been widely studied for their potential 
applications in nanomedicine. Due to the fact that MNPs can be detected and manipulated by remote 
magnetic fields, it opens a wide opportunity for them to be used in vivo. Nowadays, MNPs have been used 
for diverse applications including magnetic biosensing (diagnostics), magnetic imaging, magnetic 
separation, drug and gene delivery, and hyperthermia therapy, etc. This review aims to provide a 
comprehensive assessment of the state-of-the-art biological and biomedical applications of MNPs. In 
addition, the development of high magnetic moment MNPs with proper surface functionalization has 
progressed exponentially over the past decade. Herein, we also reviewed the recent advances in the 
synthesis and surface coating strategies of MNPs. This review is not only to provide in-depth insights into 
the different synthesis, biofunctionalization, biosensing, imaging, and therapy methods but also to give an 
overview of limitations and possibilities of each technology. 
Keywords: magnetic nanoparticle, nanomedicine, magnetic biosensing, magnetic imaging, magnetic 
separation.  
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1 Introduction 
Magnetic nanoparticles (MNPs), with the size between 1 nm and 100 nm, are one important nanomaterial for 
science and technology in the past two decades. The unique characteristics of MNPs, such as high surface to 
volume ratio and size-dependent magnetic properties, are drastically different from those of their bulk materials. 
MNPs have been receiving tremendous attention in multiple areas such as data storage, spintronics, catalyst, 
neural stimulation, and gyroscopic sensors, etc.1-20 Nowadays, many methods have been developed to fabricate 
MNPs due to their wide applications, and there are mainly two approaches to obtain MNPs: top-down approach 
and bottom-up approach. MNPs with a properly functionalized surface can be physically and chemically stable, 
biocompatible, and environmentally safe. In addition, biological samples exhibit virtually no magnetic 
background, thus high sensitivity measurements can be performed on minimally processed samples in MNP-
based biological and biomedical applications. Thus, MNPs have been successfully applied as contrast enhancers 
in magnetic resonance imaging (MRI) 21-26, tracer materials in magnetic particle imaging (MPI) 27-33, tiny heaters 
in magnetic hyperthermia 34-37, carriers for drug/gene delivery 38-43, tags for magnetic separation 12, 44-49, etc. The 
ease of synthesis and facile surface chemistry, with comparable size to biologically important ligands, has 
generated much eagerness in applying MNPs to clinical diagnostics and therapy 50-58.  
    Herein, we have reviewed different strategies for the synthesis and biofunctionalization of MNPs, as well as 
the diagnostic and therapeutic applications of MNPs. Our aim is to discuss the challenges of working with MNPs 
while giving an overall overview of the state-of-the-art.  
2 Physical Properties of Magnetic Nanoparticles (MNPs) 
2.1 From Bulk Material to Nanoparticle 
MNPs, with comparable sizes to biologically important objects 59, have demonstrated unique properties such as 
larger surface-to-volume ratio, excellent reactivity, exceptional magnetic response compared to their bulk 
materials 60, 61. Materials such as pure metals (Fe, Co, Ni, etc.), alloys (FeCo, alnico, permalloy, etc.), and oxides 
(Fe3O4, -Fe2O3, CoFe2O4, etc.) with high saturation magnetizations are preferred for the production of MNPs. 
Although pure metals are able to yield higher saturation magnetizations, they are not suitable for clinical use due 
to the high toxicity and oxidative properties. One of the most widely used MNP types is iron oxide considering 
the high chemical and colloidal stability, high biocompatibility, and low cost.  
    Magnetic properties of MNPs, such as magnetic moment and anisotropy constant, depend strongly on their size 
and shape. Magnetic moment (𝜇) is the product of magnetization (𝑀) and magnetic core volume 𝑉𝑚 which is the 
 4 
most important property of MNP for nanomedicine related applications. A higher magnetic moment yields a more 
pronounced detection signal (for magnetic biosensing and imaging-related applications) as well as a larger 
magnetic force (for magnetic manipulation and drug/gene delivery related applications) 62, 63. Due to the lack of 
translational crystal symmetry in the surface layer (also known as surface spin-canting effect) 64-67, the magnetic 
properties of surface layer are very different from the interior region of MNP, as a result, decreased saturation 
magnetizations 𝑀𝑠  and increased anisotropy constants are observed in MNPs compared to their corresponding 
bulk materials. This spin-canting effect is not affected by the organic capping but the magnetic core size of MNP 
68 and the particle synthesis methods 69. It can be understood in terms of a core-shell structure (as shown in Figure 
1(a)) where the spins in the magnetic core are fully aligned along the applied magnetic field while the spins in the 
shell are canted relative to the field. For a spherical MNP, its saturation magnetization can be modeled by 70: 
𝑀𝑠 = 𝑀𝑠𝑏(1 − 2𝛿 𝐷⁄ )
3 (1) 
Where 𝑀𝑠𝑏  is the saturation magnetization of the bulk material, 𝐷 is the diameter of the magnetic core, and 𝛿 is 
the thickness of the spin canting layer. Dutta et al. 71 have reported the fitted values of 𝛿 = 0.68 𝑛𝑚 and 𝑀𝑠 =
92 𝑒𝑚𝑢 ∙ 𝑔−1 (~4.76 × 105  𝐽 𝑚3𝑇⁄ ) for magnetite nanoparticles based on experimental results. 
 
 
Figure 1. (a) Schematic view of general spin canting geometry, the core-shell model. (b) Theoretical 𝑀𝑠 (blue 
solid line) and 𝐾𝑒𝑓𝑓  (orange solid line) versus magnetite nanoparticle diameter 𝐷 at 300 K. Horizontal dash-dot 
lines exhibit 𝑀𝑠𝑏  and 𝐾𝑏, respectively. Theoretical data are compared with experimental ones. Blue diamonds 
from 72, blue hexagons from 73, orange triangle from 74, orange squares from 75, orange pentagon from 31, and 
orange circle from 76. ((b) reprinted with permission from reference 67, copyright 2017 IOP Publishing) 
 
On the other hand, due to the spin-canting effect, the observed anisotropy constants from MNPs are always 
larger than their corresponding bulk materials 67. The effective anisotropy constant 𝐾𝑒𝑓𝑓  is modeled by 
77:  
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𝐾𝑒𝑓𝑓 = 𝐾𝑏 + (
6Φ
𝐷
) 𝐾𝑠 (2) 
Where, 𝐾𝑏  and 𝐾𝑠 are the bulk and surface anisotropy constants, respectively. For spherical particles, Φ = 1. 
Demortiere et al. 77 have reported the fitted values of 𝐾𝑏 = 1.04 × 10
5 𝑒𝑟𝑔 ∙ 𝑐𝑚−3 (~1.04 × 104  𝐽 𝑚3⁄ ) for bulk 
magnetite, and 𝐾𝑠 = 3.9 × 10
−2 𝑒𝑟𝑔 ∙ 𝑐𝑚−2 (~3.9 × 10−5  J m2⁄ ). The effective anisotropy is also affected by the 
MNP shape (i.e. shape anisotropy), for spherical nanoparticles, shape anisotropy is negligible compared to surface 
anisotropy. 
    These two models in equations (1) & (2) have been applied to predict the magnetic properties of magnetite 
nanoparticles with respect to magnetic core diameters (𝐷) , and they were examined by comparing with 
experimental data from literature available (see Figure 1(b)). 
2.2 From Multi-domain to Single-domain MNPs 
Bulk magnetic materials are composed of microscopic crystalline grains (also known as polycrystalline). Each 
grain is single crystal, with crystal lattices oriented in different directions, has an easy axis of magnetization. To 
reduce the magnetostatic energy, each grain spontaneously divides into many magnetic domains separated by 
domain walls, called multi-domain state. The magnetizations of different domains point in different directions in 
a more or less random manner while the magnetization within each domain points uniformly to one direction. As 
a single crystal grain splits into multi-domains, the magnetostatic energy reduces but meanwhile extra energy 
(domain wall energy) is required. Magnetic domains stabilize to a critical size 𝐷𝑐𝑟𝑖𝑡 when the energy cost of 
generating an additional domain wall is equal to the magnetostatic energy saved. This critical size varies for 
different magnetic materials (proportional to(𝐴 2𝐾⁄ )1 2⁄ ) which is determined by the material properties such as 
exchange stiffness (𝐴) and anisotropy constant (𝐾), usually, the critical size is between 10 nm and 100 nm. The 
critical size range is bounded by a lower limit (superparamagnetism) and a higher limit (multi-domain), see Figure 
2(a). The critical sizes for the observation of superparamagnetism, single-domain, and multi-domain behaviors of 
a variety of common ferromagnetic fine nanoparticles can be found from reference 78. 
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Figure 2. (a) Transition from superparamagnetic to the multi-domain region. The inset figure shows qualitative 
behaviors of the size-dependent coercivities of MNPs. 𝐷𝑠𝑝  and 𝐷𝑐𝑟𝑖𝑡 are, respectively, the transition sizes from 
superparamagnetic to a blocked state, and from single-domain to multi-domain regions. (b) Magnetization curve 
of superparamagnetic nanoparticles measured at room temperature by VSM. Superparamagnetic nanoparticle 
shows zero magnetic coercivity. (c) Schematic view of energy barrier and thermal fluctuation. ((b) reprinted with 
permission from reference 79, copyright 2015 AIP Publishing LLC) 
 
    Single-domain MNPs are particles with internal magnetizations pointing uniformly in one direction, thus, these 
particles bear magnetizations equal to their spontaneous magnetization 𝑀𝑠, and they have the largest possible 
magnetic moment of  𝜇 = 𝑉𝑚𝑀𝑠, where 𝑉𝑚 is the magnetic core volume of the particle. The magnetization of a 
single-domain particle rotates as one single giant magnetic moment (called the macro-spin approximation) under 
external magnetic fields and its hysteresis has been well described by the Stoner-Wohlfarth model.  
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    Due to the magnetic anisotropy, the magnetic moment of a single-domain MNP has two preferred orientations 
which are antiparallel to each other and are both aligned along its “easy axis”. These two preferred directions are 
energy minimums separated by an energy barrier of 𝐸𝑏 = 𝐾𝑒𝑓𝑓𝑉𝑚, which prevents the magnetic moment from 
flipping from one direction to the other. However, thermal fluctuations cause the magnetic moment to rotate in a 
random manner. As is shown in Figure 2(c), under a finite temperature 𝑇, if the energy barrier 𝐸𝑏  is comparable 
to or smaller than the thermal fluctuation energy 𝑘𝐵𝑇, the magnetic moment jumps from one direction to the other 
frequently during a measurement time period of 𝜏𝑚, then the observed net magnetization is zero, resulting in 
superparamagnetism. Under a specific measurement time 𝜏𝑚 and temperature 𝑇, there is a critical size 𝐷𝑠𝑝  at 
which the transition from single-domain to superparamagnetic nanoparticle occurs. Again, this critical size 𝐷𝑠𝑝  
varies for different magnetic materials, usually in the range of several to several tens nanometers. Due to the fast 
flipping of magnetic moments in superparamagnetic nanoparticles, they show zero magnetic moments in the 
absence of an external magnetic field. When an external field is applied, their magnet moments tend to align along 
the field resulting in nonzero net magnetization, the magnetic moment of superparamagnetic nanoparticle vs 
applied field is a reversible S-shaped curve as shown in Figure 2(b). 
2.3 Superparamagnetism 
At a finite temperature 𝑇 , there is a finite probability that the magnetic moment of a superparamagnetic 
nanoparticle flips between two preferred directions. The mean time between two flips is called zero-field Néel 
relaxation time expressed as: 
𝜏𝑁 = 𝜏0𝑒𝑥𝑝 (
𝐾𝑒𝑓𝑓𝑉𝑚
𝑘𝐵𝑇
) (3) 
Where, 𝜏0 is attempt time (attempt period), which is around 10
−10~10−9  seconds depending on the material, 
and 𝑘𝐵 is Boltzmann constant. 
It can be seen from equation (3) that the Néel relaxation time is an exponential function of the particle size, and 
it can vary from nanoseconds for nanoparticles to years for larger particles or bulk materials. Néel relaxation 
process is the rotation of magnetic moment inside a stationary MNP (see Figure 3(b)). 
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Figure 3. (a) Magnetic core diameter 𝐷 and organic capping layer with thickness 𝑑. (b) Néel relaxation process 
is the rotation of magnetic moment inside a stationary particle. (c) Brownian relaxation process is the rotation of 
entire particle with its magnetic moment. (d) Néel, Brownian, and effective relaxation time as a function of MNP 
core diameter, 𝑇 = 293 𝐾. Viscosity of the MNP solution is assumed to be 𝜂 = 1 𝑐𝑝. (e) The AC magnetic 
susceptibility has two components: in-phase and out-of-phase. The figure shows the normalized 𝜒′ and 𝜒′′ as 
functions of 𝜔𝜏 , the out-of-phase component 𝜒′′  reaches a maximum when 𝜔𝜏 = 1 . ((d) reprinted with 
permission from reference 79, copyright 2015 AIP Publishing LLC) 
 
    However, for most biomedical applications, superparamagnetic nanoparticles are dispersed in suspensions (also 
called ferrofluid) where the magnetic relaxivity is a joint effect of both Néel and Brownian processes (see Figure 
3(b) & (c)) 67, the zero-field Brownian relaxation time is given as: 
𝜏𝐵 =
3𝜂𝑉ℎ
𝑘𝐵𝑇
 (4) 
where 𝜂 is the fluid viscosity, 𝑉ℎ is the hydrodynamic volume of MNP. 
The Néel and Brownian relaxation models from equations (3) & (4) are quite simplified, representing a general 
guideline of non-interacting superparamagnetic nanoparticles under zero magnetic field. Within the assumption 
of independence of Néel and Brownian processes, the effective relaxation time is given as: 
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𝜏 =
𝜏𝑁𝜏𝐵
𝜏𝑁+𝜏𝐵
 (5) 
Figure 2(b) shows the magnetization curve of an ensemble of 25 nm iron oxide superparamagnetic 
nanoparticles measured by Vibrating Sample Magnetometer (VSM) at room temperature 79. Since above the 
blocking temperature 𝑇𝐵, the measurement time 𝜏𝑚 is larger than 𝜏𝑁, so the nanoparticle appears to be in the 
superparamagnetic state and its magnetic moment flips several times during one measurement period, thus, the 
measured magnetization is averaged to zero when the external field 𝐻 = 0 𝑂𝑒. As the external magnetic field is 
applied, the magnetic moments of nanoparticles tend to align with the field direction, resulting in a net 
magnetization. Hence, superparamagnetic nanoparticles show paramagnetic behavior under small magnetic fields, 
and the magnetization curve is a reversible S-shape, which is usually simplified by the Langevin model: 
𝑀(𝐻) = 𝑀𝑆𝐿 (𝜇0
𝜇𝐻
𝑘𝐵𝑇
) (6) 
where 𝜇0 is the magnetic permeability of vacuum, 𝐿(𝑥) is the Langevin function, 𝐻 is the applied magnetic field.  
2.4 Magnetic Susceptibility 
Magnetic susceptibility 𝜒 is a dimensionless proportionality constant that describes the degree of magnetization 
of a material in response to external magnetic field, it is the ratio of magnetization 𝑀 to the field 𝐻. When 
subjected to alternating current (AC) magnetic field, the magnetization of MNP may not be able to follow the AC 
field due to its finite rate of magnetic relaxation, thus, a phase delay between the AC field and the magnetization 
is introduced. This property introduces a complex magnetic susceptibility 𝜒(𝜔), which can be calculated by the 
Debye model 80: 
𝜒(𝜔) =
𝜒0
1+𝑗𝜔𝜏
= 𝜒′ + 𝑗𝜒′′ = |𝜒|𝑒𝑗𝜑 (7) 
and 
𝜒′ =
𝜒0
1+(𝜔𝜏)2
 (8) 
𝜒′′ =
𝜒0𝜔𝜏
1+(𝜔𝜏)2
 (9) 
𝜑 = 𝑡𝑎𝑛−1(𝜔𝜏) (10) 
where 𝜒0 is the DC (direct current) field susceptibility, 𝜔 is the angular frequency of AC field, 𝜒
′ and 𝜒′′ are the 
in-phase and out-of-phase components, 𝜑 is the phase delay. 
Figure 3(e) shows the normalized 𝜒′ and 𝜒′′ as functions of 𝜔𝜏, the out-of-phase component 𝜒′′ reaches a 
maximum when 𝜔𝜏 = 1, this property is exploited for monitoring the binding of target biomolecules to MNPs in 
magnetic relaxometry based biosensors. Furthermore, 𝜒′′ also holds great significance in magnetic hyperthermia 
applications. The power generation 𝑃 (also called specific absorption rate, SAR) by MNPs under an AC magnetic 
field is defined by Rosensweig theory (RT) 81: 
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𝑃 =
1
2
𝜇0𝜔𝜒′′𝐻0
2 (11) 
where 𝐻0 is the magnitude of AC magnetic field 𝑯. This equation leads to a global maximum of 𝑃 when 𝜔𝜏 = 1, 
which defines the critical frequency for the system 82. SAR is a parameter commonly used to characterize the 
goodness of a given combination of colloidal suspension and magnetic field characteristics to convert the 
magnetic field energy into thermal energy. 
2.5 Magnetic Relaxivity 
The element that contains an odd number of protons and/or neutrons in its nucleus, such as 1H, 2H, 13C, 14N, 15N, 
17O, 23Na, 31P, etc., exhibits intrinsic magnetic moment (namely, spin), which is the primary origin of the magnetic 
resonance signal. Single proton hydrogen 1H is one particularly favorable element for nuclear magnetic resonance 
(NMR) and magnetic resonance imaging (MRI) applications due to its high intrinsic sensitivity and high 
abundance in water and lipid molecules. For example, the magnetic resonance signals from water or fat within 
the patient’s tissue are monitored for MRI applications, these magnetic resonance signals come from the 1H which 
is abundant in water and lipid molecules 83. Although NMR has relatively low sensitivity, the MNP provides 
inherent signal amplification to NMR since each MNP cluster affects billions of adjacent water protons. Thus, 
MNPs have been widely used as contrast agents in NMR and MRI applications 84, 85.  
Under an externally applied static magnetic field (𝑯0 along the 𝒛-direction), the water proton nuclei align 
parallel to 𝑯0 and precess with the Larmor frequency. As shown in Figure 4(a), when a resonant radio frequency 
(RF) pulse is applied perpendicular to 𝑯0, these nuclei are excited to antiparallel states. Upon the removal of RF 
pulse, these nuclei relax to equilibrium states. In the presence of MNPs, the dipolar magnetic field increases the 
local field inhomogeneity. When water molecules diffuse to the periphery of MNPs, the coherent precessions of 
water proton spins are perturbed. As a result, the net effect is a change of magnetic resonance signal, which can 
be measured as the shortening of the longitudinal and transverse relaxation time of surrounding water proton spins. 
The longitudinal relaxation time 𝑇1 (also known as spin-lattice, or relaxation in the z-direction), as shown in 
Figure 4(b), is a measure of the time taken for the 𝑧 component of the nuclear spin magnetization, 𝑀𝑧, to return 
to its thermal equilibrium value 𝑀0: 
𝑀𝑧(𝑡) = 𝑀0 − [𝑀0 − 𝑀𝑧(𝑡 = 0)] ∙ 𝑒
−𝑡 𝑇1⁄  (12) 
where the 𝑧 component magnetization recovers to 63% of its equilibrium value within a time period of 𝑇1. 
On the other hand, the transverse relaxation time 𝑇2 (also known as spin-spin, or relaxation in the x-y plane), 
as shown in Figure 4(c), is the decay constant of the net magnetization 𝑀𝑥𝑦 (magnetization perpendicular to 𝐻0): 
𝑀𝑥𝑦(𝑡) = 𝑀𝑥𝑦(𝑡 = 0) ∙ 𝑒
−𝑡 𝑇2⁄  (13) 
where the transverse magnetization drops to 37% of its original magnitude within a time period of 𝑇2. 
Correspondingly, the longitudinal and transverse relaxation rates are reciprocals of 𝑇1 and 𝑇2: 
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𝑅1 =
1
𝑇1
 (14) 
𝑅2 =
1
𝑇2
 (15) 
    Magnetic relaxivity is the intrinsic property of MNP contrast agent, it reflects the MNP’s ability to increase the 
longitudinal and transverse relaxation rates of the surrounding nuclear spins, denoted as  𝑟1 and 𝑟2, respectively: 
𝑟1 =
∆𝑅1
∆𝐶
 (16) 
𝑟2 =
∆𝑅2
∆𝐶
 (17) 
Where, 𝐶 is the concentration of MNPs. Thus, the relaxivities 𝑟1 and 𝑟2 have units of 𝑛𝑀
−1 ∙ 𝑠−1.  
 
 
Figure 4. (a) The transition from parallel to antiparallel states upon the application of RF pulse. (b) Longitudinal 
relaxation time 𝑇1. (c) Transverse relaxation time 𝑇2. 
 
The sensitives of NMR and MRI are largely dependent on the relaxivities of the MNP contrast agents. Generally, 
the transverse relaxivity values 𝑟2 of MNPs are greater than longitudinal relaxivity 𝑟1, thus MNPs are mainly used 
as a 𝑇2 -modulating agent and MNPs with higher 𝑟2  are preferred for these applications 
86. In addition, the 
relaxivity is also dependent on the magnitude of 𝐻0 
87, temperature, and solvent (e.g., blood, water, plasma). 
Magnetic properties of MNPs such as saturation magnetization, size 88, and shape 89-91 are reported to affect the 
relaxivity. Furthermore, the aggregated and evenly dispersed MNPs can also lead to a 𝑇2 variation. In real NMR 
experiments, the measured transverse relaxation time (denoted as 𝑇2
∗) is always less than or equal to 𝑇2, which 
arises from the inhomogeneities in the main magnetic field. 
In recent years, lots of work have been carried out to increase the 𝑟2 of contrast agents in order to improve the 
sensitivity of NMR and MRI 92-94. In a recent report by Zhou et al. 90, they artificially introduced local magnetic 
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field inhomogeneity by clustering of MNPs as well as designing MNPs with heterogeneous geometries (e.g., size 
and shape) to enhance the 𝑟2. Mohapatra et al. 
95 have reported iron oxide nanorods with very high 𝑟2 relaxivity 
value of 608 𝑚𝑀−1𝑠−1 , which is mainly attributed to the higher surface area and anisotropic morphology. 
Furthermore, alloy-based nanomaterials are good candidates for developing 𝑇2  contrast agents with high 𝑟2 
relaxivity values, graphene oxide-Fe3O4 (GO-Fe3O4) MNP composite 94 and  Zn2+ doping controlled MNPs 96 
have been reported to effectively increase the 𝑟2 value. The classical outer-sphere relaxation theory points out that 
𝑟2 𝑟1⁄  increases with increasing particle sizes 
97, thus, larger MNPs or MNP clusters are more likely to be better 
𝑇2-modulating agents. 
2.6 Dipolar Interactions 
MNPs have been successfully applied in magnetic biosensing (i.e. diagnosing), trapping, and therapeutic 
platforms. Most of these applications are based on the magnetic properties of MNPs, which may vary depending 
on the MNP aggregation state, namely, the interparticle distances. In a cluster of MNPs, the dipolar interactions 
(also known as dipole-dipole interactions or dipolar coupling) affect substantially to the collective magnetic 
behaviors 67, 82, 98. To be specific, this dipolar interaction modifies the magnetic relaxation time 67, 82, susceptibility, 
remanence, coercivity, and blocking temperature 99 of MNPs. As a result, the performance of hyperthermia 
therapy 82, 100, 101 and magnetic particle imaging (MPI) 102 can be drastically modified. As the MNP concentration 
increases, the interparticle distance decreases, and the dipolar interaction increases, which alters the magnetic 
response of the whole ferrofluid. For MNPs under an applied magnetic field 𝑯, the total magnetic field acting on 
one MNP is the sum of external magnetic field 𝑯 and the dipolar field 𝑯𝑑𝑖𝑝 which is generated by surrounding 
MNPs: 
𝑯𝑑𝑖𝑝 =
1
4𝜋
∑
3(𝝁𝑗∙𝒆𝑖𝑗)∙𝒆𝑖𝑗−𝝁𝑗
𝑟𝑖𝑗3
𝑖≠𝑗  (18), 
Where, 𝒆𝑖𝑗 is the unitary vector joining two MNPs, 𝑟𝑖𝑗 is the distance between these two MNPs. This dipolar field 
is inversely proportional to the cube of interparticle distance. 
    As is mentioned in section 2.1, the organic capping layer will not affect the magnetic properties of MNPs, 
which suggests a possibility of tailoring the interparticle distances by controlling the thickness of capping layer. 
This organic capping layer can effectively prevent direct surface contact and increase the average interparticle 
distance thus, reducing the dipolar interactions. 
2.7 Multicore MNPs 
Superparamagnetic NPs show zero remanent magnetization due to thermal fluctuation, as the NP size increases 
they become ferrimagnetic and show hysteresis. For many MNP-based medical and biological applications, larger 
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MNPs are preferred to yield higher specific heating losses and higher magnetic moments. However, the non-zero 
remanent magnetization of larger MNPs leads to agglomeration in the absence of external magnetic field even 
with polymer coatings. Once the MNP agglomerates reach to the size of a red blood cell (which is around 6 m), 
they are at risk of blocking blood vessels and cause dangerous side effects to the patients 103. To prevent 
agglomeration, the multicore MNPs (also called superferrimagnetic multicore NPs, i.e., MCNPs) are proposed, 
they are clusters of smaller superparamagnetic NPs embedded in a polymer matrix. Typically, these multicore 
MNPs are between 20 and 100 nm and consist of superparamagnetic NPs about the size of around 10 nm. 
Multicore MNPs show much smaller remanent magnetization compared to the single core MNPs with similar 
sizes, which could effectively prevent the agglomeration. Multicore MNPs have shown excellent potential for 
applications in magnetic diagnostics and therapy. Lartigue et al. 104 reported magnetically cooperative multicore 
MNPs with enhanced hyperthermia efficiency and MRI 𝑇1 and 𝑇2 contrast effects. By applying electrostatic 
colloidal sorting while preserving a superparamagnetic-like behavior, they have successfully enhanced magnetic 
susceptibility and decreased surface disorder of multicore MNPs. Kratz et al. 105 presented a novel aqueous 
synthesis for generating multicore MNPs that are suited for both MRI and MPI and allows the combination of 
these two techniques for biomedical imaging. Lai et al. 106 presented multicore MnFe2O4@SiO2@Ag MNPs with 
both magnetic and plasmonic properties, which holds great promise for applications in magnetic/photo-thermal 
hyperthermia and surface-enhanced Raman spectroscopy. 
3 Synthesis of MNPs 
Overall, there are two main approaches to prepare nanoparticles: top-down approach and bottom-up approach. 
The schematic drawing of these two approaches is shown in Figure 5. In the top-down approach, such as 
lithography and ball milling, bulk materials (or thin films) are broken down into micrometer or nanometer size. 
In the bottom-up approach, however, nanoparticles form from atoms followed by nucleation and growth process. 
There are several bottom-up methods used to prepare nanoparticles, such as gas-phase condensation, chemical 
vapor deposition, and wet chemical method.  In this section, we will focus on these two methods: ball milling 
method as top-down approach and gas-phase condensation method as bottom-up approach.  
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Figure 5. Schematic drawing of a typical top down and bottom up approach for nanoparticle synthesis. (a) Bulk 
material. (b) Grinding ball. (c) Nanoparticles. (d) Clusters. (e) Atomic level.  
3.1 Ball Milling Method 
Ball milling method developed by John Benjamin 107 in 1970 is used to prepare powders with reduced size. Fecht 
et al. 108 proposed the working mechanism of ball milling method. Schematic drawing of the working principle 
of ball milling method is shown in Figure 6. 
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Figure 6. Schematic representation of ball milling mechanism for the formation of crystalline nanoparticles. 
 
    There are three stages for ball milling method to prepare nanoparticles. In the first stage, deformations and 
dislocations are introduced into bulk materials during collisions between balls and bulk materials. The dislocation 
density keeps increasing with milling time. In the second stage, small grains (nanoscale) are formed due to the 
accumulation, recombination or rearrangement of dislocations. In the third stage, the grain orientation became 
random. And then grains at the edge of bulk material are peeled off. Thus, the nanoparticles are obtained from 
bulk materials. The relationship between grain size of the prepared nanoparticle and the milling time could be 
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estimated by the equation 𝑑 = 𝑘𝑡−2 3⁄ , where 𝑑 is the grain size of the nanoparticle, 𝑘 a constant related with 
specific system and materials, and 𝑡 the milling time 109. 
    However, there is a limitation to the particle size obtained in a specific ball milling system. If the milling time 
is too long the so-called cold-welding effect, where nanoparticles will be welded together resulting in big particles 
110, 111. When particles have smaller sizes, for examples sub-micrometer, the surface energy of the particles plays 
a more important role, and particles are more likely to aggregate together to reduce their surface energy. In order 
to reduce the cold-welding effect, a surfactant is used to lower down the surface energy and reduce the cold-
welding effects 112, 113. Chen et al. 110 reported a surfactant-assisted ball milling method to prepare de-
agglomeration graphite nanoparticles. The agglomerate size varies from 1 µm to 30 µm and much smaller 
nanoparticles (< 100 nm) are obtained when using Phosphoric acid dibutyl ester as a surfactant. Even through 
surfactant-assisted ball milling could produce particles with smaller size, the size distribution is usually very wide. 
How to control the size distribution of particles prepared by ball milling method is another problem need to be 
solved. Liu et al. 114, 115 proposed an idea to select particles with different size via centrifugal separation with 
different “settling-down” time of a particle solution. In their experiment, different kinds of nanoparticles, such as 
Fe, Co, FeCo, SmCo, and NdFeB, are obtained with much narrower size distributions. Nanoparticles with high 
saturation magnetizations such as Fe, FeCo are focused due to their high magnetic moments. Figure 7 exhibits 
the TEM images of Fe and SmCo5 nanoparticles prepared by a surfactant-assisted ball milling approach. The Fe 
nanoparticle size ranges from 4 nm to 6 nm as shown in Figure 7(a) and (b). SmCo5 nanoparticles with size 
ranging from 3 nm to 13 nm are obtained after 5 h milling, and elongated shape SmCo5 nanoparticles are achieved 
with even longer milling time of 25 h, as shown in Figure 7(c) and (d). Poudyal et al. 116 reported Fe, Co, and 
FeCo nanoparticles using surfactant-assisted ball milling method. Uniform size (~ 6 nm) particles could be 
obtained by properly controlling the ball milling parameters and applying size selection process.  
For bio-applications, ball milling with a surfactant is used because of reduced cold-welding effect, small 
particle size and narrow particle size distribution, which makes surfactant-assisted ball milling a suitable way to 
prepare particles for bio-related applications.  
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Figure 7. TEM images of the nanoparticles prepared by milling Fe powders for (a) 1 h, and (b) 5h, and by milling 
SmCo5-based powder for (c) 5 h, and (d) 25 h. (Reprinted with permission from reference 115, copyright 2006 AIP 
Publishing LLC) 
 
3.2 Gas-phase Condensation (GPC) Method 
Gas-phase Condensation (GPC) is a bottom-up approach in which atoms (from the sputtering or evaporation) 
nucleate and grow to form nanoparticles. The particle size and crystallinity are well-controlled by this method 
while the throughput is generally low compared to ball milling methods. Granqvist and Buhrman 117 firstly used 
the GPC method to prepare ultrafine particles in 1976. In this GPC system, the atoms are generated from an 
evaporation source. Then atoms nucleate and grow into nanoparticles in static inert gas. However, both the particle 
size and crystallinity are out of control. Sattler et al. 118 introduced differential pressure and a skimmer into the 
GPC system, and the size of nanoparticles obtained is under control, but this method is still unable to control the 
crystallinity of nanoparticles. Later in 1991, a sputtering source is adopted. Thus, more materials are suitable for 
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preparing nanoparticles 119. Yamamuro et al. 120 pointed out the key factor to get monodispersed nanoparticles is 
to separate nanoparticles’ nucleation and growth process into different space regions. In 2006, Wang et al. 121 
reported that field-controlled plasma heating effect could help control the phase and crystallinity of NPs. For 
instance, disordered A1 phase and ordered L10 phase FePt nanoparticles are successfully prepared using the GPC 
method by adjusting the plasma heating effects. Moreover, meta-stable phase body-centered tetragonal Fe 
nanoparticles are also successfully made by this method 122. 
    We will focus on GPC system with sputtering sources in this section. In the GPC system, atoms are kicked off 
from a target forming atom vapor near the target surface. High sputtering pressure (several hundred mTorr) is 
applied to form nanoparticles instead of thin films since the mean free path of atoms is much smaller at high 
sputtering pressure (several hundred mTorr). In this case, these sputtered atoms will collide with argon atom, and 
energy will transfer from atoms to argon atoms. Thus, the temperature of atoms is cooling down and nucleation 
and growth will happen when the temperature is low enough. The size of the nanoparticle is dependent on the 
sputtering current, magnetic field intensity at the target surface, sputtering pressure and gas flow rate. Due to 
magnetron sputter sources, many kinds of particles have been successfully prepared, such as high magnetic 
moment MNPs (Fe, Co, FeCo), core-shell nanocomposite, and MNPs with the tunable magnetic property.  
First, well-crystallized high moment FeCo nanoparticles are successfully synthesized by a GPC method. The 
average size of FeCo nanoparticle is around 12 nm showing superparamagnetic properties, which is suitable for 
bio-related applications such as GMR based biosensors 123, 124. As shown in Figure 8, both spherical and cubic 
shape FeCo nanoparticles could be made using GPC method by adjusting the plasma heating effects. Some other 
high moment nanoparticles such as Fe and Co are also successfully synthesized using a GPC method. 
 
 
Figure 8. TEM bright field images of FeCo nanoparticles with different shapes, (a) spherical and (b) cubic. 
(Reprinted with permission from reference 125 , copyright 2007 Elsevier) 
 
 19 
    Second, to make nanoparticles easier for following surface chemical modification, core-shell nanoparticle 
structure is a good candidate. Gold is good for the surface modification, making it a good candidate for shell 
material for high moment magnetic nanoparticles. To make a gold shell for magnetic nanoparticles, atom diffusion 
at the nanoscale should be well-understood. There are two effects competing during shell formation: diffusion via 
concentration gradient and surface segregation. The first one is to make atoms distribution uniform and the other 
one is opposite. Therefore, surface segregation should be a major effect in obtaining core-shell nanoparticles 126. 
Figure 9 shows the TEM images of FeCo nanoparticles with Au shell prepared by the sputtering-based GPC 
method. Core-shell nanoparticles could also be prepared by multiple ion cluster source (MICS), in which three 
independent magnetron sources replace the single source as discussed above 127. In MICS setup, one source could 
be used as core NPs synthesize and others for shell materials. In this case, some core@shell, core@shell@shell 
structures are prepared 128. As shown in Figure 10, nanoparticles with Co/Ag/Au core@shell@shell structure are 
prepared, demonstrated by scanning TEM (STEM) image and energy dispersive X-ray spectroscopy (EDS) line 
scan and electron energy loss spectroscopy (EELS) element mapping of these nanoparticles. 
 
 
Figure 9. Morphology and composition distribution of FeCo–Au nanocrystals. (a) High angle annular dark field 
(HAADF) image showing clear core-shell structure due to the contrast between the different materials of core 
and shell. (b) Composition distribution of a cross section of a single FeCo–Au nanocrystal, acquired by EDS line 
scan. The nanocrystal is shown in the inset. The line indicates the path of the electron beam. (Reprinted with 
permission from reference 129, copyright 2007 AIP Publishing LLC) 
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Figure 10. Core@shell@shell Co@Ag@Au nanoparticles. a) Representation of the complex Co@Ag@Au 
structure together with the expected EDS intensity profiles. b) Cs-corrected STEM representative image of a 
Co@Ag@Au NP. c) EDS line scan performed at the Co, Ag and Au, along the line depicted in Figure 4b. d) 
EELS compositional analysis for the Co L3,2 edge. The dashed line represents the outer limit of the NP. e) EELS 
map for the Ag M4,5 edge. f) STEM image together with the corresponding Co and Ag EELS concentration maps 
superimposed. (Reprinted with permission from reference 128, copyright 2014 The Royal Society of Chemistry) 
 
3.3 Other Nanoparticle Fabrication Approaches 
Besides ball milling method and gas-phase condensation system, there are some other approaches to prepare 
nanoparticles such as wet chemical way 130, 131, chemical vapor deposition 132, 133, thermal decomposition 134, 135, 
etc. Figure 11 shows the SEM and TEM images of FeCo nanocubes prepared by a wet chemical method. The size 
of FeCo nanocubes ranges from 60 nm to 270 nm. The morphology and dimensions of the FeCo nanotube can be 
adjusted by controlling the concentration of cyclohexane and PEG-400, the reaction time, and the molar ration of 
Fe2+ and Co2+ in the reaction solutions. The saturate magnetization of 68 ± 6 nm FeCo nanocubes is 211.9 emu/g. 
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Figure 11. (a) SEM and (b) TEM micrographs of FeCo nanocubes, obtained by reaction of 0.1 M Fe2+ and Co2+ 
with hydrazine for 30 min in the presences of 2.8 M PEG-400 and 0.14 M cyclohexane. The inset is an illustration 
of the nanocube. (c) TEM image and (d) SAED pattern of a single FeCo alloy nanocube oriented along [001]. (e) 
TEM image, (f) SAED pattern, and (g) HRTEM image of a FeCo alloy nanocube oriented along [110]. (Reprinted 
with permission from reference 130, copyright 2008 American Chemical Society) 
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4 Surface Coating Strategies 
The biocompatibility and chemical stability of MNPs can be enhanced by conjugating chemical compounds such 
as polyethylene glycol (PEG), chitosan, lipid, proteins, etc. 136. In most biological applications, the solubility and 
chemical stability of the MNPs should be well controlled in different environments both in vivo and in vitro. It is 
also necessary to prevent MNPs from aggregation and precipitation while maintaining their biocompatibility and 
chemical stability 136. To this end, surface coating strategies are needed to facilitate the application of MNPs in 
nanomedicine. In this section, both organic and inorganic coating strategies with regard to different areas of 
applications will be reviewed. 
4.1 Organic Coating 
MNPs synthesized through organic solutions are monodisperse, single crystalline with the high magnetic moment. 
But since these particles often turn out to be hydrophobic, additional surface modification techniques are needed 
137. In general, the organic coating techniques on MNPs can be divided into covalent and absorption processes. 
As is shown in Figure 12, the covalent coating can be further divided into grafting-to, grafting-from, and grafting-
through techniques 138. 
 
 
Figure 12. Schematic representation of different coating techniques for MNPs. 
     
    By reacting with hydrophilic molecules, the hydrophobic surfactants on the nanoparticles can be replaced with 
hydrophilic ligands. Polyethylene glycol (PEG) is the most commonly used polymer for such ligand exchange 
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process due to its biocompatibility and also the ability to reduce any non-specific reaction between MNPs and 
proteins 139. For example, Xie et al. 140 synthesized monodispersed 9 nm Fe3O4 nanoparticles and functionalized 
them with dopamine (DPA) terminated PEG. The coating process is shown in Figure 13. Since DPA moiety has 
higher affinity to the Fe3O4 surface, it was first linked to PEG and was then used to replace the oleate and 
oleyamine on the particle surface. It was found that not only did these MNPs have higher stability and no 
agglomeration in water and physiological environment, they were also undetectable by the body immune system, 
which made them promising candidates for drug delivery applications. Besides PEG, other polymers such as 
dendrimers 141, polyethylene oxides 142 and dextrans 143 have also been used in the ligand exchange. In addition, 
small molecules that have high affinity to the MNP surface, such as the previously mentioned DPA, can also be 
directly used in the ligand exchange 144, 145. 
 
 
Figure 13. Surface modification of Fe3O4 nanoparticles via DPA-PEG-COOH. X=CH2NHCOCH2CH2. 
 
    Although PEG is commonly used for the requirement of minimizing non-specific protein absorption, it has a 
major drawback, which is the tendency of oxidative degradation. To solve this problem, polyzwitterions, which 
are made from zwitterionic repeat units without net charge, were developed 138. Since zwitterionic moieties are 
the main component of cell membranes and exhibit long circulation time, which can largely reduce the cytotoxic 
side effects. Several approaches are available for the functionalization of polyzwitterions. For example, von der 
Lühe et al. 146 successfully coated polydehydroalanine (PDha) on the surface of MNPs. The functionalization can 
also be accomplished by simply inducing polyzwitterions during the synthesis of MNPs. 
    In addition to surface coating, MNPs can also be encapsulated in a shell to increase their biocompatibility and 
hydrophilicity. Cheng et al. 147 embedded MNPs in a copolymer matrix, i.e., poly(D,L-lactide–co–glycolide)–
block–poly(ethylene glycol) (PLGA-b-PEG-COOH) and managed to tune the size of the MNPs by altering 
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solvent type, polymer concentration, and solvent : water ratio. They were the first group to report a linear 
correlation between polymer concentrations and the size of the resulting MNPs, which makes it possible to 
precisely control the size of the MNPs to fulfill different requirements for drug delivery in various organs. Other 
copolymers, such as polystyrene-co-poly-(acrylic acid) (PS-co-PAA) 148 and poly(D,L-lactide)–block–
poly(ethylene glycol) (PLA–b–PEG) 149 are also used in similar applications.  
4.2 Inorganic Coating 
Silica is one of the most widely used inorganic coating materials, which is biocompatible and can provide non-
aggregated and stable suspensions 150. A silica outer shell also allows for the subsequent functionalization of 
alkoxysilanes. Chen et al. 151 demonstrated the nontoxicity of FePt NPs with a 17 nm thick silica shell and proved 
that FePt NPs can be internalized by tumor cells. Furthermore, it was found that these particles were strong 𝑇2 
agents and thus had great potential for the design of diagnostic and therapeutic agents for drug delivery and 
hyperthermic tumor ablation. The capability of cellular imaging and in vivo MRI applications was also 
demonstrated.  
    To obtain a better control of the magnetic properties of the silica-coated MNPs, especially to satisfy the 
temperature requirement for hyperthermia treatments, the influence of silica coating on the magnetization and the 
Currie temperature of the MNPs were studied. It was shown that at room temperature, the magnetization can be 
decreased by 32% by silica coatings under a magnetic field of 1 kOe due to the presence of diamagnetic shells 
152. The Currie temperature can also be reduced by 7% due to the interaction between silica and the MNP surface. 
Thus, a trade-off between the biological stability and magnetic properties should be considered for silica coated 
MNPs. 
    Compared to organic coatings, inorganic coatings are more frequently used in hyperthermia treatments. Since 
metals are conducting materials, metallic coatings allow for inductive heating under an AC magnetic field. Due 
to its easy conjugation with many biomolecules such as DNAs and proteins, gold has become the optimal metallic 
coating for MNPs 153. While gold coatings can simplify subsequent bio-functionalization processes and protect 
the internal MNPs from oxidation, they inevitably induce changes in the magnetic properties of the resulting NPs. 
Presa et al. 154 synthesized FePt nanoparticles from high-temperature solution phase and tried to optimize the 
number of gold coatings on the MNP surface. It was shown that at low temperature, the coercivity of the FePt-
Au NPs decreases about 3 times and the blocking temperatures also reduce to the half compared to uncoated NPs, 
which was attributed to the reduction of surface anisotropy due to the interaction between gold atoms and the 
FePt NPs. Yano et al. 154 also did a similar study on this issue and pointed out the direct relationship between 
coercive field and magnetic anisotropy, but the mechanism underlying in the gold-FePt interaction is still not 
clear. 
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5 MNPs for Diagnosis 
Early detection of diseases allows for therapeutic intervention in the early stages, which is the key to successful 
treatment. With the rapid developments in nanotechnology, optical and electrochemical sensors have been applied 
as high sensitivity diagnosis platforms. However, considering their susceptibility to interferences from 
unprocessed biological samples, the optical and electrochemical sensors require complicated sample 
pretreatments 155. On the other hand, magnetic nanomaterial-based sensing systems are attracting much attention 
for the immunoassay applications since biological samples exhibit negligible magnetic susceptibility, which 
makes very high signal-to-noise ratio (SNR) magnetic sensing possible even in a minimally processed biofluidic 
sample.  
5.1 Magnetoresistive (MR) Sensors 
5.1.1 Giant Magnetoresistive (GMR) Biosensors 
Since its discovery in 1988, GMR sensors have been widely used in hard disk drives 156, 157, position sensing 158, 
electrical current measurement 159, 160, as well as biomarker detection 161, 162 163, 164. GMR effect is observed in 
structures with alternating ferromagnetic and nonmagnetic metal layers (see Figure 14(a)). When exposed to the 
external field, the magnetization orientation of the “free” ferromagnetic layer with respect to the “pinned” 
ferromagnetic layer will change, which will result in the change of the resistance of the whole device 165, 166. The 
ability of a GMR sensor to respond to the external field is characterized by the GMR ratio, which can be expressed 
as:  
𝐺𝑀𝑅 =
R𝐴𝑃−R𝑃
R𝑃
× 100% (19). 
    The first GMR based sensing system for biomarker detection was performed by Baselt et al. 167 The Bead Array 
Counter (BARC), which includes multilayer GMR sensors and magnetic microbead tags, was developed and 
exhibited great potential in the measurement of intermolecular forces during biomolecular recognition processes. 
In the past 20 years, lots of research has been carried out to optimize the structure of the magnetic immunoassay 
and the performance of the GMR detectors. The most widely used magnetic immunoassay is built up based on 
antibody-antigen reactions. For example, in the GMR based probe station system developed by Wang et al.,168, 
169 the MNPs were functionalized with streptavidin, which can bind to the biotinylated detection antibody. During 
the detection process, the analyte was captured by the capture antibody functionalized on the GMR sensor surface. 
Then, the detection antibody was added and can only bind to the sites with the analyte. The functionalized MNPs 
were subsequently attached to the detection antibody as the final layer. Under the external field, the MNPs were 
magnetized, whose dipolar field (also known as the stray field) can be sensed by the GMR sensors underneath 170 
(see Figure 14(c)). To realize on-site diagnosis, several handheld systems were also developed 171, 172. With the 
size of a snack container and a user-friendly interface, the system can be used by non-technicians with minimum 
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expertise (see Figure 14(e)(f)). Apart from antibody-antigen reactions, aptamers can also be used in the 
immunoassay (see Figure 14(d)) 173. 
The MNPs used in the immunoassay are often embedded in a polymeric matrix (also known as multi-core 
MNPs) and their diameters can vary from tens of nanometers to hundreds of nanometers 174-177. Compared to 
other biomarker tags, MNPs exhibit superior performance due to low background noise, low possibilities of 
aggregation due to superparamagnetism, and high biological compatibility 178. To date, the detection of various 
biological targets has been demonstrated, such as DNAs 173, viruses 171, 179 and food pathogens 180, 181. Chugh et. 
al 182-184 has demonstrated that GMR in its IC form has also been quite active in non-invasive determination of 
primary healthcare parameters such heart rate, respiration rate and blood pressure.  
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Figure 14. (a) An example for GMR spin valve stacks. (b) An example for MTJ stacks. (c)Magnetic immunoassay 
on GMR sensor surface. (d) GMR detection based on aptamers. (e) and (f) are GMR-based handheld systems 
developed by two different groups. ((e) reprinted with permission from reference 171, copyright 2017 American 
Chemical Society, (f) reprinted with permission from reference 172 , copyright 2016 Elsevier) 
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    However, a major problem associated with GMR-SV sensors is that they exhibit Barkhausen noise due to the 
formation and depletion of the magnetic domains during the spin direction reversal of the sensing layer. This 
causes changes in resistance which may occur in the absence of the MNPs, and when used for the detection of 
MNP-labels/biomarkers, it can result in false signal detection. Nevertheless, this problem can be resolved if 
necessary by applying a strong pre-magnetizing field is applied (e.g., by integrated microconductors) to reduce 
the order the internal magnetic domains prior to the sample run 185. 
5.1.2 Magnetic Tunnel Junction (MTJ) Biosensors 
In addition to GMR sensors, MTJ sensors are also promising candidates as the detectors for the magnetic 
immunoassays. The basic structure of a MTJ consists of a thin insulating tunnel barrier sandwiched between two 
ferromagnetic layers (Figure 14(b)). The tunneling magnetoresistance (TMR) ratio is defined in the same way as 
the GMR ratio. While the GMR ratio of the spin valve sensors commonly used in the bio-detection is less than 
20% 168, the TMR ratio of the MTJ sensors with MgO tunnel barriers can be over 200% at room temperature 186. 
MNPs and the immunoassays are integrated with MTJ sensors in the same way as with GMR detectors. Sharma 
et al. 187 have developed a sensing system based on MTJ sensors for the detection of pathogenic DNA. Firstly, 
the probe oligonucleotides complementary to the target DNA strands are immobilized on the sensor surface. After 
hybridization between probe DNA and target DNA, the streptavidin-coated MNPs were added. The real-time 
signal change of the injection, binding and washing steps of the MNPs can be read out from the MTJ sensor arrays. 
The detection limit for Listeria DNA can be as low as 1 nM. 
    Cardoso et al. 188 studied the difference of MTJ sensors and spin valve (SV) sensors in the detection of 130 nm 
MNPs. It was found that MTJ sensors had a higher signal-to-noise ratio (SNR) than SV sensors but will reach a 
limit at a current of 900 μA. The SNR of SV sensors, however, will increase continuously with the applied current 
and will only be limited by the heat generation. In the detection of MNPs, SV sensors also exhibited higher signal 
level and sensitivity despite the high TMR ratio of the MTJ sensors, which can be attributed to the increased 
distance between MNPs and sensor surface due to the top electrodes of MTJ sensors. Despite greater linearity 
and sensitivity of TMR sensors over SV, a major problem for TMR is shot noise that arises from the discontinuity 
in the electron transport paths is present in MTJs unlike that in spin valves and GMR multilayers. This is due to 
the existence of an insulating barrier in MTJs; the conduction medium is discontinuous for MTJs.  
    Another probable source of error in both SV and MTJ sensors can be from the sample itself in cases where 
there are MNPs from clusters, may be because of the presence of surface charges resulting in an erroneous 
detection 185. Such clustering can be avoided, with suitable surface modification and sheathing of the magnetic 
material as discussed previously in Section 4. Other possible sources of errors in MR sensors are the thermal noise 
(which are non-magnetic in origin but has a direct effect on the resistance of the sensor) and stray field from 
MNPs. New, exciting applications of these sensors could be in MCG and magnetic encephalography provided 
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there field of operation can be shifted to elevated frequencies, giving them better noise level, and multiple 
calibration steps are carried out before use. 
5.2  Micro-Hall (μ Hall) Sensors 
Since Hall voltage is proportional to the external field, Hall sensors can provide a linear response to the 
dipolar/stray field from MNPs and are only sensitive to its perpendicular component. Thus, they can map out the 
trajectory of moving magnetic particles and have been used in many areas such as drug delivery, medical imaging, 
and biomarker detection 189. In 2002, Besse et al. 190 fabricated a highly sensitive silicon Hall sensor with the 
ability to detect one single magnetic microbead of 2.8 μm by standard complementary metal-oxide-semiconductor 
(CMOS) technology. Later, devices based on InAs quantum well (QW) semiconductor heterostructures were 
developed. Phase-sensitive detection was employed and demonstrated even better SNR for micrometer and 
nanometer-sized magnetic particles 191. Michele et al. 192 also performed single-particle detection using InSb 
double Hall cross with an area of 1 μm2. By sweeping DC field and taking the normalized difference between the 
in-phase signals, the susceptibility curve for the target magnetic particle can be measured. 
Aledealat et al. 193 was the first group to integrate microfluidic channel with micro-Hall sensors (see Figure 
15). With a cross-shaped InAs quantum well micro-Hall sensor, the real-time signal from beads moving within 
and around the sensing area in the microfluid channel can be detected and distinguished by polarities. The first 
attempt to use micro-Hall sensors in biological detection was made by Issadore et al. 194, in their work, the MNPs 
were bound to the bacterial cell wall and acted as the magnetic tags. The stream with target cells was flowed 
through the hall sensor surface in a microfluidic channel and was confined in the vertical direction. It was shown 
that the sensing system can reliably distinguish Gram-positive from Gram-negative species and requires much 
smaller sample volume (1 μL) compared to flow cytometry. The detection limit of the system was ~10 bacteria, 
which was comparable to that of culture tests, but the assay time was 50 times faster. Sandhu et.al 195 had studied 
some practical sensors based on Hall Effect for biomedical instrumentation. 
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Figure 15. Schematic illustration of the microfluid channel integrated with micro-Hall sensor. (a) SEM image of 
the central region of an InAs micro-Hall sensor and immobilized SPM beads. (b) 𝑉𝐻 as a function of time for 
crosses (1)–(4). The increase in 𝑉𝐻 for crosses (1)–(3) and its drop for cross (4) as B was applied agrees with the 
expected signals based on a dipolar stray field representation of SPM beads. (Reprinted with permission from 
reference 193, copyright 2010 Elsevier) 
 
5.3 NMR-based Diagnostics 
NMR-based diagnostics exploits MNPs as proximity sensors (contrast agents), which modulate the 𝑇2 of water 
molecules adjacent to the target-MNP aggregates. When MNPs specifically bind to their target molecules through 
affinity ligands, they form magnetic clusters which lead to a faster decay of NMR signal or shorter transverse 
relaxation time 𝑇2 of the surrounding water protons. The NMR-based biosensing technology collects signals 
directly from the whole volume of sample (volume-based biosensor), which effectively shorten the immunoassay 
time than that of surface-based sensors such as GMR, MTJ, and μHall sensors. This class of sensors (volume-
based biosensors) are more flexible, smaller in size, and suitable for on-site diagnosis.  
5.3.1 Magnetic Relaxation Switching (MRSw) Assay 
As is mentioned in section 2.5, the transverse relaxivity 𝑟2 of MNPs are greater than longitudinal relaxivity 𝑟1, 
thus MNPs are mainly used as 𝑇2-modulating agents for NMR related applications. In MRSw-based nanosensors, 
the change of 𝑇2 mainly comes from the aggregation degrees of MPNs in the presence of target analytes. To date, 
there are two types of detection mechanisms that have been reported so far 196-200, namely, 𝑇2 decreases with the 
aggregation of MNPs in type I system (see Figure 16(a)), and 𝑇2 increases with the aggregation in type II system 
(see Figure 16(b)). The outer sphere relaxation theory gives a theoretical explanation for these two systems. In 
type I system, the aggregation of MNPs cannot overcome the thermal randomization thus it’s in a motional 
averaging (MA) model where the diffusional motion of water molecules is fast enough to average out the magnetic 
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field generated by MNP aggregations. In this MA model (type I system, Figure 16(a)),  𝑇2  is inversely 
proportional to the number of MNPs in aggregation and the concentration of aggregations. Thus, the more 
severely the MNPs aggregate, the lower the 𝑇2 will be. However, once the aggregation is big enough to overcome 
the thermal randomization, the system becomes a static dephasing model (SD) where the free water protons 
contribute mainly to 𝑇2. If the size of MNP aggregation is in SD regime, the 𝑇2 increases with the increasing size. 
In this SD model (type II system, Figure 16(b)), a small number of aggregates and large space between aggregates 
lead to most water protons’ failure to experience the magnetic field inhomogeneity 155, in this diffusion-limited 
case, 𝑇2 increases as the size of MNP aggregates increases. This diffusion-limited case applied when larger sized 
MNPs are used. 
Koh et al. 201 explored the behavior of MNP-based type I and micrometer-sized particle (MP) based type II 
MRSw assay systems. Both systems successfully detected the presence of Tag peptide of influenza virus 
hemagglutinin (IVH) and a monoclonal antibody to that peptide (anti-Tag), while type II MP based assay shows 
better sensitivity than type I MNP based assays. Chung et al. 202 reported the detection of kidney injury markers 
KIM-1 (kidney injury molecule-1) and Cystatin C with as low concentration of 0.1 ng/ml and 20 ng/ml 
respectively. MRSw also found its applications in the detection of virus such as herpes simplex virus 1 (HSV-1) 
203, ions such as Hg2+ 204, 205, Pb2+ 206, 207 and Cd2+ 208, and breast cancer cells, colon cancer cells, and lung cancer 
cells 209.  
Besides its applications in disease diagnosis, MRSw has also been applied as a sensitive and rapid method for 
detecting foodborne pathogens such as Listeria monocytogenes 210, Salmonella enterica 211, etc. Chen et al. 212 
combined the NMR and magnetic separation into a one-step platform. Based on the difference in the separation 
speed of small (30 nm) and large (250 nm) MNPs, both MNPs are conjugated with antibodies which specifically 
recognize the targets, then large MNPs are employed for separation and small MNPs are probes for MRSw sensing.  
Luo et al. 213 have demonstrated a portable MRSw-based biosensor system for the detection of Escherichia coli 
(E. coli) O157:H7 from drinking water and milk samples within one minute. Their device reached a detection 
limit of 76 cfu/mL in water samples with a linear dynamic detection range of 4 orders of magnitude.  
Recently, some groups have developed miniaturized devices based on NMR for POC applications 202, 213-217, 
bringing down the cost, size, and sample use by orders of magnitude. As shown in Figure 16(c)&(d), a NMR 
system is developed by Lee et al. 217, it consists of a permanent magnet that generates stable magnetic field 𝑯0, 
a RF generator with coil close to sample to generate RF pulses, a signal receiver to amplify NMR signals and 
external electronics for synchronizing the different components and store the data 218.   
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Figure 16. (a) MRSw-based detection mechanisms (type I and type II) using small MNPs. (b) MRSw-based 
detection mechanism (type II) using micro-sized magnetic beads. (c) Schematic diagram of the portable NMR 
system developed by Lee et al. 217. This system consists of microfluidic networks for sample handling and mixing, 
an array of microcoils for NMR measurements, miniaturized NMR electronics and a permanent magnet. (d) A 
photograph of the portable NMR system. For user-inputs and data sharing, the system communicates with external 
devices. ((c) adapted with permission from reference 217, copyright 2008 Springer Nature, and (d) reprinted with 
permission from reference 219, copyright 2011 The Royal Society of Chemistry) 
 
5.3.2 Magnetic Resonance Imaging (MRI) 
One of the most well-known applications of NMR in nanomedicine is MRI. MRI is a medical imaging technique 
that measures the NMR signals from protons in human bodies, and its performance can be significantly improved 
by administering contrast agents. The MRI contrast agents can be divided into two groups: positive (𝑇1-weighted) 
and negative (𝑇2-weighted) contrast agents. Positive contrast agents shorten the 𝑇1 of surrounding protons and 
result in brighter MR images, while negative contrast agents shorten the 𝑇2 of protons and lead to darker MR 
images. The mechanisms of MNP-based NMR have been discussed in the foregoing sections. After intravenous 
or oral administration, the MNPs (or USPIONs) can shorten the 𝑇2 (or 𝑇1) relaxation times of surrounding water 
protons inside various organs, leading to contrast in the MR images. 
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    Since the first commercialization of 𝑇1-weighted positive MRI contrast agent Gd-DTPA (Magnevist, Schering 
AG) in 1988, there have been large numbers of gadolinium-based contrast agents dominating the market (see 
Figure 17(a)). However, some recent studies have pointed out the concern of gadolinium-associated nephrogenic 
systemic fibrosis (NSF) 220-223 and FDA has issued warnings to limit the usage of gadolinium-based contrast 
agents 224. Nowadays, MNPs have emerged as excellent MRI contrast agents, they have proved superior 
biocompatibility and safety profiles 225. MNPs with core sizes larger than 10 nm are used as 𝑇2-weighted MRI 
contrast agents, and ultra-small SPIONs (USPIONs) with core size less than 5 nm are reported as promising 𝑇1-
weighted MRI contrast agents 226-228 (see Figure 17(a)).  
    Based on the classical outer-sphere relaxation theory, larger MNPs with a high magnetic moment and 𝑟2 
relaxivities are chosen as 𝑇2-weighted (negative) MRI contrast agents. There are two types of 𝑇2-weighted 
(negative) MNP contrast agents that are clinically approved, namely: ferumoxides (Feridex in the USA, Endorem 
in Europe) with particle sizes of 120 to 180 nm, and ferucarbotran (Resovist) with particle sizes of about 60 nm. 
The principal effect of this negative contrast agents is on 𝑇2
∗ relaxation and thus MR imaging is usually performed 
using 𝑇2 − 𝑇2
∗-weighted sequences in which the tissue signal loss is due to the susceptibility effects of the iron 
oxide core 225. The main drawback of negative imaging agents is, however, inherently related to the contrast 
mechanism that they generate. MNPs produce a dark signal (a signal decreasing effect) which could be confused 
with other pathogenic conditions and render lower contrast compared to 𝑇1  contrasted images. This main 
drawback has limited their clinical usages in low signal body regions, in the presence of hemorrhagic events, and 
in organs with intrinsic high magnetic susceptibility (such as lung) 229. Some techniques such as spin-echo 
sequences 230, 231, inversion recovery ON-resonant water suppression (IRON)-MRI 232 and the usage of micron-
sized iron oxide particles 233 have been proposed to overcome these challenges. 
On the other hand, the 𝑇1-weighted MRI contrast agents yield better imaging quality and they can effectively 
diagnose the normal and lesion tissues especially in blood imaging 234-236. Kim et al. 237 reported one type of 
efficient 𝑇1 contrast agent which is synthesized via the thermal decomposition of the iron-oleate complex in the 
presence of oleyl alcohol. These 3 nm-sized USPIONs with a high 𝑟1 value of 4.78 𝑚𝑀
−1𝑠−1 and low 𝑟2 𝑟1⁄  ratio 
of 6.12. The synthesis methods for USPIONs include thermal decomposition, polyol, coprecipitation, or reduction 
precipitation and 𝑟1 values vary from 2 to 50 𝑚𝑀
−1𝑠−1 are also reported by other groups 224, 227, 228, 238, 239.  
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Figure 17. (a) Schematic view of MRI contrast agents: 𝑇1 contrast agents such as Gd-DTPA and USPIONs, 𝑇2 
contrast agents such as IONs, dual mode contrast agents such as the core/shell/shell structured NPs. (b) MRI 
images and their color-coded images of AFIAs and conventional contrast agents. Fe3O4@SiO2@Gd2O(CO3)2 (i), 
CoFe2O4@SiO2@Gd2O(CO3)2 (ii), CoFe2O4@SiO2@Eu2O(CO3)2 (iii), CoFe2O4@SiO2@Dy2O(CO3)2 (iv), 
MnFe2O4@SiO2@Gd(BTC)(H2O) (v), ZnFe2O4@SiO2@[ImH][Mn(BTC)-(H2O)] (vi), Gd-DTPA (vii), Feridex 
(viii), and H2O (ix). Images of contrast agents are taken by using 3.0 T MRI at the identical metal concentrations. 
(c) & (d) Plots of 𝑅1  and 𝑅2  vs concentration of the metal; 𝑟1  and 𝑟2  of mAFIA, 
ZnFe2O4@SiO2@[ImH][Mn(BTC)-(H2O)], are∼2-fold larger than those of conventional contrast agents. ((b)-(d) 
reprinted with permission from reference 240, copyright 2014 American Chemical Society) 
 
Recently, dual-mode contrast agents are emerging to eliminate the possible ambiguity of a single-mode contrast 
agent (either 𝑇1 or 𝑇2) when some of the in vivo artifacts are present, it is the combination of simultaneously 
strong 𝑇1 and 𝑇2 contrast effects in a single contrast agent (see Figure 17(b)). This dual mode contrast agent can 
potentially provide more accurate MRI via self-confirmation with better differentiation of normal and diseased 
areas. The core@shell-type 𝑇1 − 𝑇2 dual mode nanoparticle contrasts have been described by several groups 
240-
245. For example, Choi et al. 242 reported the MnFe2O4@SiO2@Gd2O(CO3)2 core@shell@shell nanoparticles as 
dual-mode MRI contrast agents, where the SiO2 layer was used to modulate the magnetic coupling between 𝑇1 
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contrast material Gd2O(CO3)2 and 𝑇2 contrast material MnFe2O4. By increasing the SiO2 layer thickness (varies 
from 4 nm to 20 nm), the 𝑟1 value increased from 2.0 to 33.1 𝑚𝑀
−1𝑠−1, and the 𝑟2 value decreased from 332 to 
213 𝑚𝑀−1𝑠−1. In Figure 17(c)-(d), Shin et al. 240 measured different combinations of core@shell@shell dual 
mode artifact filtering nanoparticle imaging agent (AFIA) [𝑇2 core (superparamagnetic nanoparticle) @SiO2@𝑇1 
shell (paramagnetic material)] and demonstrated its superior relaxivities (𝑟1 and 𝑟2) than Magnevist (𝑇1 contrast 
agent) and Feridex (𝑇2 contrast agent). Other structures such as iron core with ferrite shell nanoparticles 
246, 247, 
ultrasmall mixed gadolinium-dysprosium oxide (GDO) nanoparticles 248 and core@shell structured manganese-
loaded dual-mesoporous silica spheres (Mn-DMSSs) 249 have also been reported as 𝑇1 − 𝑇2 dual mode contrast 
agents. 
 
5.4 Superparamagnetism-based Diagnostics  
5.4.1 Brownian Relaxation-based Assay 
As is aforementioned in section 2.3, superparamagnetic nanoparticles exhibit non-linear magnetic response curve 
with zero coercivity. Under an external AC magnetic field 𝐻, the magnetic moment inside superparamagnetic 
nanoparticle tends to align with the field while this process is countered by Néel and Brownian relaxations that 
randomize its magnetic moment 250, 251. For superparamagnetic iron oxide nanoparticles (SPIONs) dispersed in 
liquid solution, the Brownian relaxation is the dominating obstructing factor when the magnetic core size is above 
20 nm while Néel relaxation dominates when core size is below 20 nm 79, 252. For those Brownian relaxation-
dominated SPIONs, the extent of the disorder is linked directly to environmental conditions 253, such as 
temperature 254, 255, viscosity 79, 256-258, and the ligand binding states 80, 259-262. In this section, we focus on the 
Brownian relaxation dominated SPIONs for immunoassay applications. For Brownian relaxation dominated 
SPIONs, the effective relaxation time is expressed as 𝜏 ≈ 𝜏𝐵 =
3𝜂𝑉ℎ
𝑘𝐵𝑇
. SPIONs are functionalized with ligands 
(such as aptamers, proteins, antibodies, etc.) which can specifically recognize and bind to target analytes from 
minimally processed biofluid samples, this successful binding process increases the hydrodynamic size of 
SPIONs thus the effective relaxation time. Hence, a larger phase delay between its magnetic moment and the AC 
magnetic field is detected, and the magnitudes of harmonics are attenuated as a result (see Figure 18(h)&(i)).  
    In 2006, Krause group 263 and Nikitin group 264 have independently proposed a mixing frequency method based 
Brownian relaxation dominated SPIONs for immunoassay applications. As shown in Figure 18(a)-(g), two drive 
fields 𝐻 = 𝐴𝐻𝑐𝑜𝑠(2𝜋𝑓𝐻𝑡 + 𝜑𝐻) + 𝐴𝐿𝑐𝑜𝑠(2𝜋𝑓𝐿𝑡 + 𝜑𝐿) are applied to drive SPION suspension, the response 
signal generated at 𝑓𝐻 ± 2𝑓𝐿 (3
rd harmonics), 𝑓𝐻 ± 4𝑓𝐿 (5
th harmonics), etc., are collected. These harmonics are 
highly specific to the nonlinearity of the magnetization curve of the SPIONs. The amplitude of low frequency AC 
field, 𝐴𝐿, is chosen to periodically switch on and off the capability of SPIONs to further magnetization, while the 
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high frequency AC field is used to modulate the harmonics into high frequency regions where the pink noise (1 𝑓⁄  
noise) is lower. Due to the time-varying magnetization of the SPIONs, a time-variant voltage is induced in the 
receive coil due to the SPION harmonic response (Figure 18(b)). On the other hand, Rauwerdink and Weaver et 
al. 255, 260, 262, 265 proposed a mono-frequency method based Brownian relaxation dominated SPIONs for 
immunoassay applications, its setup is similar to the 1D MPI: they applied an AC magnetic field 𝐻 =
𝐴𝑐𝑜𝑠(2𝜋𝑓𝑡 + 𝜑) to drive SPIONs, the nonlinear magnetic response induces higher harmonics at frequencies of 
3𝑓 (3rd harmonic),  5𝑓 (5th harmonic), etc., the information such as SPION-target analyte binding states can be 
extracted from these harmonics in the same way as we described before. 
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Figure 18. (a) Schematic setup of mixing frequency method-based magnetometer. Microcontroller with 
electronics part provide sine waves to drive the excitation coils, the generated signals are picked up by receive 
coil and harmonics are filtered and read into the microcontroller via the ADC. (b) Sectional view of the coils. (c)-
(g) SPIONs are exposed to two AC magnetic field with frequencies of 𝑓𝐻 and 𝑓𝐿 (d). The drive field spectrum in 
(g) exhibits two distinct lines. Due to the nonlinear magnetization curve of SPIONs (c), the resulting time-
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dependent magnetization (e) saturates at higher fields, leading to higher harmonics and frequency mixing 
components in the Fourier-transformed response signal (f). (h) SPIONs are functionalized with ligands that will 
specifically bind to target analytes, this binding process increases the SPION’s hydrodynamic size as well as 
phase lag. (i) The ligands on SPIONs blocks them from non-specific binding and prevents false signal change.  
 
Since the amplitudes of harmonics increase with the number of SPIONs within the fluid sample, so phase lags 
80, 266 and harmonic ratio 265 (magnitude ratio of 5th over 3rd harmonic) are used as concentration-independent 
metrics to characterize the relaxation time as well as the binding state of SPIONs.  
    Orlov et al. 267 applied the method of registration of SPIONs by their nonlinear magnetization to a novel 
immunoassay on 3D fiber solid phase for detection of staphylococcal toxins in unprocessed samples of virtually 
any volume (see Figure 19(a)). This 3D fiber structure serves as a reaction surface to selectively filter antigens as 
well as accelerate reagent mixing. Two different setups are reported, the limits of detection (LOD) reaches to 4 
and 10 pg/mL for toxic shock syndrome toxin (TSST) and staphylococcal enterotoxin A (SEA), respectively, by 
using 30 mL samples, in 2 hours. Tu et al. 80 reported a real-time monitoring of the increase of phase delay in 3rd 
harmonic due to the binding of goat anti-human IgG to protein G coated SPIONs (see Figure 19(b)). Which is the 
first experimental demonstration of real-time detection of analyte binding process. Zhang et al. 262 demonstrated 
a rapid measurement (within 10 s) using SPIONs that conjugated with anti-thrombin ssDNA aptamers for the 
detection of thrombin, a LOD of 4 nM is reached (see Figure 19(c)). 
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Figure 19. (a) Top left: Magnetic immune-sandwich on 3D fiber filters used as a solid phase. Bottom left: SEM 
surface morphology of the cylindrical 3D fiber filters. Right: Detection of SPIONs by their nonlinear response at 
combinatorial frequencies from the whole volume of the 3D solid phase located inside a pipet tip. (b) Real time 
measurement of phase delay of IPG35 in blue curve and control sample SMG35 in red curve, with antibody 
injection at the 50th second. IPG35 are SPIONs coated with protein G that will specifically bind to IgG antibodies, 
this binding process gradually increase the hydrodynamic size of IPG35 SPIONs. SMG35 are SPIONs coated 
with PEG layer which prevents the binding of IgG onto the SPION surface, as a result, hydrodynamic size of 
SMG35 barely changed. IPG35 and SMG35 are SPIONs with average hydrodynamic sizes of 35 nm, thus, they 
exhibit same initial phase delays under the same driving fields. (c) Ratio of 5th to 3rd harmonic of 2 populations 
of SPIONs, conjugated with 15 mer and 29 mer anti-thrombin aptamer, harmonic ratios are measured as a function 
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of thrombin concentration. Three control samples are applied in this experiment to verify the specificity of the 
detection: SPIONs without aptamer functionalized, and only one population of SPION functionalized with either 
15 mer or 29 mer anti-thrombin aptamer with the increasing concentration of thrombin added. ((a) adapted with 
permission from reference 267, copyright 2012 American Chemical Society, (b) adapted with permission from 
reference 80, copyright 2011 AIP Publishing LLC, (c) adapted with permission from reference 262, copyright 2013 
Elsevier) 
 
5.4.2 Magnetic Particle Imaging (MPI) 
Magnetic particle imaging (MPI) has shown great promise in many clinical applications ranging from 
angiography to cancer theranostics and molecular imaging. This technology was first reported in 2005 by Gleich 
and Weizenecker 268, which exploits the nonlinearity of magnetization curves of SPIONs and the fact that their 
magnetization saturates at some magnetic field strength. It’s also a safer imaging method especially for chronic 
kidney disease (CKD) patients for whom iodine contrast agents are toxic. The dynamic 2D MPI and the first 
prototype of 3D real-time MPI were proposed by Gleich and Weizenecker et al. 269, 270, pushing a huge step toward 
its medical applications. A typical modality of 3D MPI system is shown in Figure 20, an AC modulation magnetic 
field 𝑯(𝒕) (it’s also called drive field) excites SPIONs and the nonlinear magnetic response 𝑴(𝒕) is induced and 
picked up by a receive coil. This magnetic response signal 𝑴(𝒕) contains not only the modulation field frequency 
𝑓 , but also a series of harmonic frequencies  3𝑓, 5𝑓, 7𝑓  etc. Higher harmonics instead of the fundamental 
frequency are used for analysis to avoid picking up the applied field. These higher harmonics can be easily 
separated from the received signal by filtering. In addition to the modulation field, an additional gradient field 
(also called selection field) is applied to localize received signals. This selection field features a field free point 
(FFP) where its magnitude is zero and increases towards the edges (see Figure 20(b)), this FFP is scanned through 
the sample following the scan trajectory. SPIONs in the FFP (red region in (b) and red curves in (c)) produce 
signals containing higher harmonics while those in the saturation region (the grey region in (b) and grey curves 
in (c)) contribute negligible signals. Tomographic MPI images are generated by scanning the FFP through the 
volume of interest. 
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Figure 20. (a) Schematic view of 3D MPI scanner. The biological sample was inserted into the x drive/receive 
coil cylinder. The selection field is generated by both the coil pair in the z-direction. The drive field coils can 
move the FFP in all three spatial directions. Only the SPIONs in the instantaneous location of the FFP generate 
MPI signals. For signal reception, each spatial component of the magnetization is detected by a respective receive 
coil. In the x-direction, the drive field coil is also used for signal reception. (b) Illustration of FFP scanning and 
distribution of magnetic field. SPIONs locate in the saturation region contribute negligible MPI signals. (c) The 
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response of the SPIONs to external magnetic fields. When the modulation field 𝑯 with a frequency of 𝑓 is applied, 
the magnetic response 𝑀(𝑡) exhibits higher harmonics (3𝑓, 5𝑓, 7𝑓, 𝑒𝑡𝑐.,) as shown in the Fourier Transformed 
signal (red curves). These higher harmonics are used for MPI image generation. When an additional selection 
field is added (grey curves), the SPIONs are magnetically saturated and the magnetic response 𝑀(𝑡) does not 
significantly change. ((a) reprinted with permission from reference 271, copyright 2017 American Chemical 
Society) 
 
MPI is an ideal tool for angiography, cellular and targeted imaging, cancer imaging, as well as imaging major 
organs and the finer coronary arteries, it allows 3D visualization, real-time imaging, and moreover, it’s radiation-
free 269, 272. MNP tracers can only be detected indirectly in MRI due to their effect on the magnetic resonance 
signal of the nuclear spin magnetization. On the other hand, MPI directly detects MNP (SPION) tracers based on 
the nonlinear magnetization response. Thus, MPI provides the distribution of tracer SPIONs deep in body with 
relatively high temporal and good spatial resolution, and the quality of MPI images are largely dependent on the 
properties of SPION tracers (core diameter, shell thickness) and scan speed 28, 273-275.  
In recent years, the development of customized SPIONs for optimized MPI is pursued with great effort. 
Dhavalikar et al. 274 reported that the MPI signal strength is related to the cubic power of the SPION core diameter 
𝐷 as long as superparamagnetic characteristics are retained. In addition, the MPI spatial resolution is heavily 
dependent on the SPION’s magnetic response curve and the gradient selection field. To be specific, a steeper 
magnetization curve confines a smaller FFP, similarly, a larger gradient selection field shrinks FFP, so a better 
spatial resolution is achieved 270, 276. Since the SPION’s magnetic response to a time-variant magnetic field is 
governed by Brownian or/and Néel relaxations, the spatial resolution is highly dependent on the SPION’s 
relaxation characteristics.  
In the first generation of MPI systems, the drive fields were around 10-20 mT in magnitude and frequency of 
25 kHz. Theoretically, an ideal SPION core size of 30 nm was proposed for this drive field setting 268. However, 
Lüdtke-Buzug et al. 277 evaluated the commercially available SPION contrast agents for MRI regarding their MPI 
performances, and he Resovist (Bayer Pharma AG), with core size much smaller than 30 nm, showed the best 
MPI performance over other tracers. Later research found that the Resovist SPIONs form aggregates and each 
aggregate still behaves like one SPION with a core size equivalent to 24 nm 29. Besides this SPION aggregation 
factor, other factors such as the SPION size distribution, anisotropy constant, morphology, shell thickness, inter-
particle interactions also affect the MPI performance 278. To sum up, the properties of SPION, as well as the 
interaction with the environment must be considered and modified for different drive field settings 33, 279, 280.  
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5.5 Surface Enhanced Raman Spectroscopy (SERS) Systems 
Raman scattering results from the radiation emitted by molecules or atoms after the bombardment of a primary 
radiation 281. The absorption of energy due to inelastic scattering of photons causes rotational and vibrational 
changes, which in turn leads to the change of the molecular dipole-electric polarizability. Raman Spectroscopy 
(RS) often uses a non-ionizing laser as the excitation source, and each peak in its signal can provide information 
on a specific chemical bond. While RS is a non-invasive and label-free technique, its signal is rather weak with a 
large fluorescence background. Moreover, there is also a limitation on the penetration depth 282. 
    In pursuit of stronger signal magnitude, SERS was firstly introduced by Fleishmann et al. 283. The substrates 
of the SERS are nano-noble metals. As the target molecules are absorbed to the surface of the substrate, there will 
be a significant increase in the Raman signal due to the excitation of the surface plasmons, which makes it possible 
for SERS to detect trace biomarkers even at a large distance from the target tissues 281. However, when only 
plasmonic NPs (eg., Au or Ag NPs) are used, the non-uniform attachment of NPs on bacteria makes it difficult to 
quantitatively measure the concentration. Detection of targets with very low concentrations is also impossible due 
to the lack of approaches to concentrate the collected samples. To solve this problem, Zhang et al. 284 developed 
multifunctional magnetic-plasmonic Fe2O3@Au core@shell NPs. With the magnetic components inside the NPs, 
the plasmonic properties can be tuned by changing the inter-particle distance via the external magnetic field (see 
Figure 21) 285. Furthermore, MNPs can also facilitate the fast concentration of bacteria cells under a point 
magnetic field. It was demonstrated that the plasmonic MNPs can concentrate the bacteria to a level of ~ 60 times 
higher than non-concentrated samples, which greatly enhanced the SEPR signal. 
 
Figure 21. Schematics of the condensation process of Au MNPs and bacteria(left) and the biomolecular 
characteristics of the bacterial cell wall that can possibly be detected by SERS (right). (Reprinted with permission 
from reference 284, copyright 2011 Elsevier) 
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Due to their superior properties in SEPR detection, plasmonic MNPs were employed in the detection of a wide 
variety of pathogen bacteria 286-288 and also in immunomagnetic separations 289. For example, Guven et al. 286 
used ion-oxide MNPs with Au nanorods (NRs) as substrates to detect E. coli, achieving a limit of detection at 8 
cfu/mL. Drake et al. 287 developed the same MNPs together with Au NPs for the detection of S. aureus. The 
detectable concentration was shown to be as low as 1 cell/mL. 
For the convenience of the readers, different MNP-based immunoassay techniques that have been reviewed in 
this paper are summarized in Table 1. 
 
Table 1. Comparison of different MNP-based immunoassay techniques 
Sensor Type MNP Assay 
Time 
Target Analyte Limit of 
Detection (LOD) 
Evaluated 
Matrices 
Ref.  
GMR 50 nm 
MNP 
30 min Pregnancy-associated 
plasma protein A 
(PAPP-A) 
1 ng/mL Blood serum 168 
Proprotein convertase 
subtilisin/kexin type 9 
(PCSK9) 
433.4 pg/mL 
Suppression of 
tumorigenicity 2 (ST2) 
40 pg/mL 
GMR 50 nm 
MNP 
10 min Influenza A Virus 
(IAV) Nucleoprotein 
(NP) 
15 ng/mL Phosphate 
buffered saline 
(PBS) 
171 
Purified H3N3 Virus 125 TCID50/mL 
GMR 50 nm 
MNP 
1 hr DNA with NRAS and 
BRAF mutations 
NA 20×saline sodium 
citrate (SSC) 
173 
MTJ 250 nm 
MNP 
30 min DNA from Listeria, 
HEV and Salmonella 
1 nM Phosphate buffer 187 
MTJ 12 nm 
MNP 
12 hr Single strand DNA 10 nM PBS 290  
 
Hall 20 nm 
MNP 
40 min S. aureus 10 bacteria Staphylococcus 
broth 
194 
Hall 250 nm 
MNP 
24 hr Oligonucleotides NA NaCl+HCl+EDTA 291 
MRSw 30 nm 
MNP 
NA Kidney injury 
molecule-1 (KIM-1) 
0.1 ng/mL Urine 202 
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Cystatin C 20 ng/mL Urine 
MRSw 50 nm 
MNP 
30 min S. enterica 103 cfu/mL Milk 211 
MRSw 30 nm 
MNP 
30 min S. enterica 104 cfu/mL Purified 212 
S. enterica 103 copy/mL Purified 
MRSw 30 nm 
MNP 
90 min Newcastle disease 
virus 
5 fM Urine 292 
MS-MRSw a) 30 nm 
MNP  
& 250 
nm MB 
30 min miR-21 from tumor 
cells 
102 cfu/mL Purified 212 
S. enterica 102 copy/mL Purified 
Brownian 
Relaxation-
based Assay 
50 nm 
MNP 
10 sec Newcastle disease 
virus 
150 pM or 0.075 
pmole 
Purified 262 
Streptavidin 4 nM or 2 pmole Purified 
Thrombin 100 pM or 0.05 
pmole 
Purified 
Brownian 
Relaxation-
based Assay 
50 nm 
MNP 
2 h Anti-thrombin 
aptamers 
4 pg/mL, 30 mL Milk 267 
Staphylococcal 
enterotoxin A (SEA) 
10 pg/mL, 30 mL Milk 
25 min Toxic shock syndrome 
toxin (TSST) 
0.1 ng/mL, 150 
L 
Milk 
SEA 0.3 ng/mL, 150 
L 
Milk 
SERS 200 nm 
Au-
MNP 
3 
hours 
4-mercatopyridine Lower than 1 nM DI water 284 
SERS 200 nm 
Au-
MNP 
NA E. coli 
P. aeruginosa 
2*105 cfu/mL DI water 284 
SERS 100 nm 
Silica-
coated 
MNP 
2 
hours 
S. aureus 103 cfu/mL Spinach wash 288 
MS-SERS b) 500 nm 
MB 
2 
hours 
TSST 1 pg/mL Purified 293 
a). Magnetic Separation and Magnetic Relaxation Switching assay 
b). Magnetic Separation and Surface-enhanced Raman Scattering assay 
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6 MNPs for Therapeutic Applications 
6.1 Drug Delivery 
The concept of using MNPs/magnetic microparticles as carriers for targeted therapeutic applications was first 
proposed in the late 1970s by Senyei and Widder et al. 294, 295. The therapeutic agents (such as cytotoxic drugs for 
chemotherapy and DNA for genetic therapy) are attached to the surface of the magnetic carrier or encapsulated 
within the polymer matrix which contains the magnetic carrier. These particle-drug complexes are injected into 
the subject either via oral or intravenous, then an externally applied high-gradient magnetic field guides and 
concentrates these complexes to the target sites (see Figure 22(a)). Once the complexes are concentrated at the 
target organ in the body, the therapeutic agents are released via enzymatic cleavage of the cross-linking molecules, 
charge interactions, pH change, degradation of the polymer matrix, or heating up the particles 296-299. This MNP-
based targeting method effectively reduces the side-effects brought by the non-specific nature of chemotherapy, 
which attacks healthy cells in addition to primary targets. Furthermore, by accurately administering and delivering 
therapeutic agents to target sites, it reduces the systemic distribution of cytotoxic compounds and enables effective 
treatment with a lower dosage. 
SPION is one of the most commonly used magnetic carriers for drug delivery, it’s often coated with an organic 
matrix such as polysaccharides, fatty acids, or other polymers to improve the colloidal stability 199, 300-302. SPIONs 
exhibit zero remnant magnetization upon the removal of the external field, which avoids the aggregations and 
facilitates their excretion from the body. Magnetic targeting is based on the theory that, a translational force will 
be exerted on the particle-drug complex in the presence of a magnetic field gradient, thus trapping the complex 
at the target site and pulling the complex towards the magnet 296, 303. A successful trapping of the particle-drug 
complex at the target site is largely dependent on the blood flow rate, surface characteristics of magnetic carriers, 
magnetic properties of particles, the magnetic field strength as well as magnetic field gradient.  
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Since the magnetic field strength decays rapidly with distance to the inner sites of the body become more 
difficult to target, which is one of the main barriers that impeding the scale-up of magnetic targeting from small 
animals to humans 297. Some groups have proposed to implant magnets (i.e. a magnetizable intraluminal stent, 
seed, etc.) in the body near the target site to circumvent this problem 304-309. Nacev et al. 310 reported pulsed 
magnetic fields to exploit the rotational dynamics of ferromagnetic rods and attain well-like curvature of the 
magnetic potential energy (see Figure 22(b)). Using this method, they focused a disperse concentration of 
ferromagnetic rods to a central target between eight external electromagnets (see Figure 22(c)&(d)).  
 
Figure 22. (a) Schematic representation of magnetic nanoparticle-based drug delivery system. (b) How forces 
generated from a magnet configuration affect particle concentration. A magnet configuration creates a magnetic 
potential energy surface (top row) that generates the magnetic forces. Magnetic forces (middle row) shape particle 
concentrations (bottom row). Particles will move from locations of high-energy states (white) to low-energy 
locations (black). Equivalently, particles will move due to either divergent forces (blue arrows) or convergent 
forces (red arrows). By applying Earnshaw’s theorem to static magnetic fields, only unstable static magnetic 
potential energy configurations were theorized to be possible, e.g., (left) a peak energy configuration and (middle) 
a saddle; (right) through the use of pulsed magnetic fields, a magnetic potential energy well is generated which is 
capable of concentrating particles to a central target. (c) Pulse sequence element for inverting the energy surface 
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of ferromagnetic rods and concentrating them at the center of the sample area. This pulse sequence element is 
repeated many times for the four directions to push and concentrate the rods to the center. (d) Focusing of 
ferromagnetic rods to a central target. Four snapshots of concentrating cobalt rods to the center of the sample area 
using dynamic magnetic inversion. The rods began optically undetectable and dispersed throughout the region. 
After 09:06 min, the rods were concentrated at the center of the sample area. Video available as Supporting 
Information. (e) Schematic illustration of the MEMSN system for pH-responsive drug delivery and magnetic 
resonance imaging. (f) In vivo MR imaging of the mice after intravenous injection of MS@S-NPs at a different 
time period, the red circles point the liver. ((a) reprinted with permission from reference 311, copyright 2009 
Elsevier, (b)-(d) reprinted with permission from reference 310, copyright 2014 American Chemical Society, (e)&(f) 
reprinted with permission from reference 298, copyright 2015 Elsevier) 
 
Besides the magnetic field issue, there are several other obstacles impeding the delivery of drug to target sites, 
such as unspecific uptake by healthy cells, rapid clearance, and aggregation during the circulation. To overcome 
these barriers, an ideal drug carrier should have the following properties: a protection layer to keep the carrier 
stable and avoid nonspecific cell uptake, tumor-targeting ability to accumulate at tumor sites, ligand-mediated 
cell adhesion for efficient cellular entry, and effective drug encapsulation to permit the drug release inside tumor 
cells only 312.  
In recent years, magnetic carriers with multiple functions including targeted anticancer drug delivery, 
hyperthermia, and imaging have been an ongoing hot topic 313-319. Hervault et al. 317 reported a dual-pH and 
thermo-responsive magnetic carrier with combined magnetic hyperthermia and anticancer drug delivery. In their 
study, a pH- and thermo-responsive polymer shell is coated onto SPION, then the anticancer drug doxorubicin 
hydrochloride (DOX) is conjugated via acid-cleavable imine linker. This complex provides advanced features for 
the targeted delivery of DOX via the combination of magnetic targeting, and dual pH- and thermo-responsive 
behavior which offers spatial and temporal control over the release of DOX. Chen et al. 298 reported a pH-
responsive nano-gated multifunctional envelope-type mesoporous silica nanoparticle (MEMSN) which is capable 
of magnetic drug delivery and in vivo MRI. They immobilized acetals on the surface of mesoporous silica and 
coupled to ultra-small lanthanide doped nanoparticles (NaGdF4) coated with TaOx layer (S-NPs) as gatekeeper 
(see Figure 22(e)). The anticancer drug DOX is locked in the pores and its burst release can be achieved under 
acidic environment on account of the hydrolyzation reactions of acetals. This MEMSN system has demonstrated 
in vivo MRI (see Figure 22(f)), passive tumor targeting, increased tumor accumulation, and it can be harmlessly 
metabolized and degraded into apparently nontoxic products within a few days. Ye et al. 316 reported a nanocarrier 
system with multiple imaging agents and an anticancer drug, they encapsulated inorganic imaging agents of 
SPION, manganese-doped zinc sulfide (Mn:ZnS) quantum dots (QDs) and the anticancer drug into poly(lactic-
co-glycolic acid) (PLGA) vesicles via an emulsion-evaporation method. Their PLGA vesicles exhibit high 
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𝑟2
∗ (523 𝑠−1𝑚𝑀−1 𝐹𝑒) relaxivity and greatly enhanced 𝑇2
∗-weighted MR imaging contrast. The Mn:ZnS QDs 
are used for fluorescence imaging to investigate the interaction between PLGA vesicles and cells. 
6.2 Hyperthermia Therapy 
Magnetic hyperthermia is a promising method for the treatment of cancer, currently in clinical trials 320-323. In 
hyperthermia therapy, an AC magnetic field is remotely controlling MNPs to induce local heat, provoking a local 
temperature increase in the target tissues where the tumor cells are present. The specificity of this technique is 
based on that tumor cells are vulnerable to temperatures above 42 C, at which the natural enzymatic processes 
that keep tumor cells alive are destroyed, so allowing the selective killing 324. The AC field used in magnetic 
hyperthermia is in the range of radio-frequency, between several kHz and 1 MHz, which is completely healthy 
and shows enough penetration depth to access inner organs/tissues in the body. Several heating mechanisms are 
possible in magnetic hyperthermia, namely, hysteresis loss, Brownian and Néel relaxations (susceptibility loss), 
and viscous heating. In comparison to these aforementioned magnetic losses, the eddy current is only significant 
in materials at centimeter scale and it’s negligibly small in MNP hyperthermia applications. 
For multi-domain MNPs, the hysteresis loss is determined by integrating the area of hysteresis loops, which is 
a measure of energy dissipated per cycle of magnetization reversal. This type of heating attributes to the shifting 
of domain walls and it’s strongly dependent on the AC field amplitude and its magnetic prehistory. As the MNP 
size reduces to the single domain, hysteresis heating is accomplished by rotating the magnetic moment of each 
MNP against the energy barrier. As the MNP size further reduces to superparamagnetic NP where the thermal 
fluctuation becomes comparable to the energy barrier, the relaxation mechanism plays a major role in magnetic 
hyperthermia. During Brownian relaxation process the thermal energy is delivered through shear stress in the 
surrounding fluid (viscous heating) and during Néel relaxation process the thermal energy is dissipated by the 
rearrangement of atomic dipole moments within the crystal 321. For those superparamagnetic NPs in a liquid 
environment, each particle maintains a constant magnetic moment and its orientation is determined by the 
effective anisotropy of the particle. An external magnetic field switches the moment from its preferred orientation 
and the relaxation of the moment back to equilibrium state releases thermal energy which results in local heating 
325. Susceptibility loss is associated with Brownian and Néel relaxations, recall equation (11), the specific 
absorption rate (SAR), 𝑃 (𝑊 ∙ 𝑚3), is related to 𝜒′′ according to 𝑃 =
1
2
𝜇0𝜔𝜒′′𝐻0
2, the global maximum 𝑃 is 
reached when 𝜔𝜏 = 1 (SAR is related to the specific loss power, namely, 𝑆𝐿𝑃 (𝑊 ∙ 𝑔−1), by the mean mass 
density of particles). The strong size dependence of relaxation time results in a very narrow maximum of the loss 
of power density. Accordingly, a good output of heating power occurs only in particle systems with narrow size 
and anisotropy distribution, as well as the mean diameter, being well adjusted in relation to the AC field frequency 
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326, 327. In addition, the efficiency of heating is largely dependent on the ability of MNPs to specifically accumulate 
in the target tissues and to achieve effective cancer therapy with a minimum dosage.  
 
 
Figure 23. (a) SAR as a function of the mean particle size 𝐷 for variable volumetric packing fraction  including 
non-interacting case (=0) and two values 𝑀𝑠 = 200 𝑒𝑚𝑢 𝑐𝑚
3⁄  and 400 𝑒𝑚𝑢 𝑐𝑚3⁄ . The solid line represents 
the solutions by means of RT. (b) SAR versus 𝐷  for different packing fractions and the values of 𝐾 =
3 × 105  𝑒𝑟𝑔 𝑐𝑚3⁄  (curve set 1), 1.5 × 105  𝑒𝑟𝑔 𝑐𝑚3⁄  (curve set 2) and 0.5 × 105  𝑒𝑟𝑔 𝑐𝑚3⁄  (curves set 3). 
Calculations correspond to log-normal distributions of size and anisotropy constants both with standard deviations 
0.1, spherically distributed anisotropy axes, and field amplitude 𝐻 = 300 𝑂𝑒. (c) Hysteresis loops for a spherical 
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(red circles, diameter 20 nm) and a cubic particle (blue squares, side 20 nm) obtained from MC simulations of an 
atomistic spin model of maghemite at low temperature. In both, uniaxial anisotropy at the core and surface 
anisotropy have been considered. Spins have been colored according to their projection into the magnetic field 
direction (z-axis) from red (+1) to blue (-1). (d) & (e) SAR values for two nanoparticle solutions of similar 
concentration (0.5 mg/mL) and size volume but different shape indicating enhancement of SAR values for the 20 
nm square nanoparticles. (d) and (e) are experimental and MC simulation results for the macrospin model with 
dipolar interactions at 300K. (f) Representative hysteresis M(H) normalized loops corresponding to different 
lengths (N) of a chain of magnetic nanoparticles with uniaxial easy anisotropy axes distributed within a cone of 
angle α = 20°. The black hysteresis curve corresponds to the case of randomly distributed non-interacting particles, 
also with the easy axes distributed at random. The inset illustrates the distribution of the axes within the cone of 
angle α, for the N = 4 chain. (g) The main panel shows the dependence of hysteresis losses 𝐻𝐿 2𝐾⁄  vs 𝐻𝑚𝑎𝑥 for 
different chain lengths, for the same α = 20° case. Inset illustrates the optimal conditions for hyperthermia 
applications, as inferred by plotting 𝐻𝐿 2𝐾 ∙ 𝐻𝑚𝑎𝑥⁄  versus 𝐻𝑚𝑎𝑥. (h) Experimental hyperthermia power of the 
0.5 % and 1 % agar cases measured at 765 kHz and 300 Oe maximum AC field, applied at different orientations 
with respect to the chains long axis (0°, 45°, and 90°; schematically illustrated in the top panel). (i) Simulated 
angle-dependence of the hysteresis losses for different chain lengths. The dotted line represents the hysteresis 
losses of a randomly distributed noninteracting system. ((a)&(b) from reference 328 under CC BY 4.0, (c)-(e) from 
reference 329 under CC BY 4.0, (f)-(i) reprinted with permission from reference 330, copyright 2014 American 
Chemical Society) 
 
In recent years, many studies have been focused on optimizing the heating efficiency in terms of MNP intrinsic 
properties such as particle size 327, 329, 331, 332, anisotropy constant 329, 333-335, saturation magnetization 328, easy axis 
orientations 330, 336, extrinsic properties such as AC field frequency 327 and amplitude 329, 334, and the role of dipolar 
interactions 322, 329, 330, 337-339.  
Ruta et al. 328 reported a kinetic Monte-Carlo (MC) method for the study of dipolar interaction, particle size, 
and saturation magnetization dependence of the SAR. The dependence of SAR on the particle diameter for two 
different values of 𝑀𝑠 is shown in Figure 23(a). For low 𝑀𝑠 = 200 𝑒𝑚𝑢 𝑐𝑚
3⁄ the dipolar interactions are weak 
and SAR does not depend on volumetric packing fraction . The MC calculation also extended toward the 
hysteretic regime in Figure 23(b), for small anisotropy constant 𝐾, increasing  can lead to enhancement of SAR 
(see curve 3) while, on the other hand, for large 𝐾, the dipolar interactions are seen to decrease the SAR value 
(see curve 1). Martinez-Boubeta et al. 329 demonstrated that single-domain cubic iron oxide particles show 
superior magnetic heating efficiency compared to spherical particles of similar size, evidencing the beneficial role 
of surface anisotropy in the improved heating power. The observed area of the hysteresis loop of the cubic particle 
is bigger than that of spherical one as shown in Figure 23(c), which is further confirmed by experimental results 
 52 
in Figure 23(d) and MC simulation in Figure 23(e).  On the other hand, the oriented attachment of MNPs into 
chain-like arrangements, biomimicking magnetotactic bacteria, have been recognized as an important pathway in 
the magnetic hyperthermia therapy roadmap. Serantes et al. 330 reported that the MNP chain has superior heating 
performance, increasing more than 5 times in comparison with the randomly distributed system when aligned 
with the magnetic field. In their study, the hysteresis cycles of an ensemble of non-interacting chains formed by 
N particles each were firstly investigated, a random angular distribution of anisotropy easy axis within the angle 
 that defines a cone around the longitudinal direction of the chain is assumed as shown in Figure 23(f). The role 
of chain length is illustrated in Figure 23(g), for the extreme cases of N = 2 and 12, respectively, the hysteresis 
area increases with increasing chain length, and it strongly depends on the filed amplitude 𝐻𝑚𝑎𝑥. Furthermore, 
they found that an increase of solution viscosity (as shown in Figure 23(h), agar > 0.5%) results in a decrease in 
the SAR. Heating power is also dependent on the relative orientation between AC field direction and chain, as 
shown in Figure 23(i).  
7 MNPs for Bioseparation and Manipulation 
7.1 Magnetic Separation 
The separation and concentration of target analytes during sample preparation are primary steps in many 
biological studies such as disease diagnosis. Although magnetic diagnosis nowadays makes it possible to conduct 
bioassays on minimally processed biofluid samples, it remains a great challenge for the detection/quantification 
of analytes that are of very low-abundance due to the current instrumental detection limits and/or interferences 
from the complicated matrix. Based on this need, the sample preparation prior to an analytical process is 
introduced in order to improve the detection limit, this sample preparation step generally involves isolation of 
analytes from sample matrix, removal of interfering species and enrichment of analytes 46, 340-342. Magnetic 
separation technique has several advantages in comparison with conventional separation methods such as 
ultrafiltration 343, 344, precipitation345, 346, electrophoresis 347-350, etc. Furthermore, magnetic separation is usually 
gentle and nondestructive to biological analytes such as protein and peptides 351. As shown in Figure 24(a), in a 
typical magnetic separation process, MNPs (or magnetic beads, MB) are employed to specifically conjugate to 
target analytes (cells, proteins, pathogenic substances, etc.), then the conjugated complexes can be easily and 
selectively removed by a subsequent magnetic separation process 352. 
Magnetic separation technique has been applied in combination with the majority of other procedures used in 
biological analysis 353. Chen et al. 212 reported a one-step sensing methodology that combines Magnetic Separation 
and Magnetic Relaxation Switching (MS-MRSw) assay for the detection of bacteria and viruses with high 
sensitivity and reproducibility. As shown in Figure 24(b), this method employs the different separation speeds of 
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MB30 (30 nm magnetic bead) and MB250 (250 nm magnetic bead) in a small magnetic field (0.01 T), and the 𝑇2 
of the water molecules around the unreacted MB30 as the readout of the immunoassay. This MS-MRSw based 
assay reached a LOD of 102 cfu/mL for the detection of S. enterica, compared to the conventional MRSw assay 
with a LOD of 104 cfu/mL. Yang et al. 293 reported a sensing methodology that combines Magnetic Separation 
and Surface-enhanced Raman Scattering (MS-SERS). They have successfully applied this method for the 
detection of chloramphenicol (CAP) and reached a LOD of 1 pg/mL with a detection range of 1 – 104 pg/mL. 
 
 
Figure 24. (a) The general procedure of magnetic separation in sample preparation for biological analysis. (b) 
Schematic illustration of the MS-MRSw sensor. MB250 and MB30 can selectively capture and enrich the target 
to form the sandwich “MB250-target-MB30” conjugate. After the magnetic separation, the 𝑇2 signal of water 
molecules around the unreacted MB30 can be employed as the readout. (c) The principle of magnetic separation-
based blood purification: elimination of pathogens. ((b) reprinted with permission from reference 212, copyright 
2015 American Chemical Society) 
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7.2 Magnetic Manipulation 
In addition to magnetic separation, this technique has also been applied to manipulate and/or sort cells, such as 
blood purification 47, 354-357, where the direct removal of disease-causing compounds is inherently attractive 
treatment modality for a range of pathological conditions such as bloodstream infections. In this magnetic 
separation-based blood purification process, MNPs/MBs conjugated with capture agents are injected into an 
extracorporeal blood circuit (see Figure 24(c)). Then the pathogen loaded MNPs/MNs are removed from the blood 
by magnetic separation. The effectiveness of blood purification is largely dependent on the target-ligand binding 
affinity. 
8 Conclusions and Future Perspectives 
The past three decades have been an exciting period in the synthesis of MNPs with interesting physical properties 
for their use in biological and biomedical applications, and many of these synthesis methods have been put in 
commercial production. To date, MNP is a burgeoning field as more improved techniques are being available for 
clinical therapy and diagnostics with increased sensitivity and efficiency. Furthermore, the surface 
functionalization of MNPs with polymers, biomolecules and ligands is crucial in order to impart biological 
recognition and interaction skills. Different kinds of MNPs have been developed to assist the bio-medical 
applications, such as MNPs with high magnetic moment, core@shell MNPs, core@shell@shell MNPs etc. The 
tunable properties due to the existence of the surface groups largely increases MNPs’ compatibility with massive 
biomedical applications. As a matter of fact, it is also important that the toxicity of nanoparticles in biomedicine 
is also taken into consideration in future. It can be foreseen that in the near future the design of MNPs will 
revolutionize the medical healthcare field by their applications in the development of ultrasensitive and 
multiplexed diagnostic systems, in vivo imaging systems with high spatial and temporal resolutions, targeted and 
remotely controlled drug/gene delivery system for effective treatment of diseases, and gene therapy.  
    MR and Hall sensors represent another equally important example which is also a product of interdisciplinary 
associations. Besides, there are some very encouraging nanotechnological methods that include molecular-ruler 
technique, nanotransfer printing and nanoskiving that are yet to be used to fabricate magnetic structures. Although 
recent in origin, micromagnetic tools for simulation and modelling of magnetic materials have opened a new 
horizon of research that helps predicting properties of biosensors and their approximate results in their 
applications even before fabrication. This makes the total process all the more cost effective, error free and 
therefore saves time. It is rational to expect that the future progress in magnetism-based nanomedicine lies in the 
development of the latest technological advances in the fields of micro- and nano-fabrication. Apart from using 
these magnetic biosensors as portable lab-on-chip devices, the fact that they were integrated with IoT platforms, 
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increased their commercial value to a great extent. This in turn had revolutionized the modern eHealth 
architecture. 
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